<!DOCTYPE html>
<html lang="tr">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Hafta 5: AraÅŸtÄ±rma TasarÄ±mÄ± - KapsamlÄ± Versiyon</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif; background: linear-gradient(135deg, #667eea 0%, #764ba2 100%); color: white; overflow: hidden; height: 100vh; display: flex; }
        .main-content { flex: 1; display: flex; align-items: center; justify-content: center; padding: 20px; }
        .sidebar { width: 450px; background: rgba(0, 0, 0, 0.3); backdrop-filter: blur(10px); padding: 20px; overflow-y: auto; border-left: 1px solid rgba(255, 255, 255, 0.1); display: none; }
        .sidebar.active { display: block; }
        .sidebar h3 { color: #ffeb3b; margin-bottom: 15px; font-size: 1.4em; }
        .sidebar h4 { color: #81d4fa; margin-bottom: 10px; margin-top: 20px; font-size: 1.2em; }
        .sidebar p { line-height: 1.6; margin-bottom: 15px; font-size: 0.95em; text-align: justify; }
        .sidebar ul { padding-left: 20px; margin-bottom: 15px; }
        .sidebar li { margin-bottom: 8px; font-size: 0.9em; }
        .slide { display: none; width: 90%; max-width: 1100px; background: rgba(255, 255, 255, 0.1); backdrop-filter: blur(20px); border-radius: 20px; padding: 40px 60px; text-align: center; border: 1px solid rgba(255, 255, 255, 0.2); box-shadow: 0 8px 32px 0 rgba(31, 38, 135, 0.37); animation: slideIn 0.6s ease-out; margin: 20px auto; min-height: 70vh; max-height: 85vh; overflow-y: auto; overflow-x: hidden; scroll-behavior: smooth; }
        .slide.active { display: flex; flex-direction: column; justify-content: flex-start; }
        /* Scroll bar styling */
        .slide::-webkit-scrollbar { width: 8px; }
        .slide::-webkit-scrollbar-track { background: rgba(255, 255, 255, 0.1); border-radius: 10px; }
        .slide::-webkit-scrollbar-thumb { background: rgba(255, 235, 59, 0.5); border-radius: 10px; }
        .slide::-webkit-scrollbar-thumb:hover { background: rgba(255, 235, 59, 0.8); }
        @keyframes slideIn { from { opacity: 0; transform: translateY(30px); } to { opacity: 1; transform: translateY(0); } }
        h1 { font-size: 3.5em; margin-bottom: 30px; background: linear-gradient(45deg, #ffeb3b, #ff9800); -webkit-background-clip: text; -webkit-text-fill-color: transparent; text-shadow: 2px 2px 4px rgba(0,0,0,0.3); }
        h2 { font-size: 2.8em; margin-bottom: 25px; color: #ffeb3b; text-shadow: 1px 1px 3px rgba(0,0,0,0.3); }
        h3 { font-size: 2.2em; margin-bottom: 20px; color: #81d4fa; }
        .content { font-size: 1.3em; line-height: 1.8; text-align: left; margin: 30px 0; }
        .highlight { background: rgba(255, 235, 59, 0.3); padding: 3px 8px; border-radius: 5px; font-weight: bold; }
        .formula { background: rgba(255, 255, 255, 0.15); padding: 20px; border-radius: 10px; font-family: 'Courier New', monospace; font-size: 1.2em; margin: 20px 0; border-left: 5px solid #ffeb3b; }
        .controls { position: fixed; bottom: 20px; left: 50%; transform: translateX(-50%); display: flex; gap: 15px; z-index: 1000; }
        .btn { background: rgba(255, 255, 255, 0.2); border: 1px solid rgba(255, 255, 255, 0.3); color: white; padding: 12px 24px; border-radius: 25px; cursor: pointer; backdrop-filter: blur(10px); transition: all 0.3s ease; font-size: 16px; }
        .btn:hover { background: rgba(255, 255, 255, 0.3); transform: translateY(-2px); }
        .btn:disabled { opacity: 0.5; cursor: not-allowed; }
        .progress { position: fixed; top: 20px; right: 20px; background: rgba(0, 0, 0, 0.5); padding: 10px 15px; border-radius: 20px; backdrop-filter: blur(10px); }
        .notes-toggle { position: fixed; top: 20px; left: 20px; background: rgba(255, 235, 59, 0.8); color: #333; border: none; padding: 10px 15px; border-radius: 20px; cursor: pointer; font-weight: bold; }
        ul { text-align: left; margin: 20px 0; }
        li { margin-bottom: 10px; font-size: 1.1em; }
        /* Fullscreen styles */
        :fullscreen .slide {
            width: 95%;
            max-width: none;
            min-height: 85vh;
            max-height: 95vh;
            padding: 30px 50px;
            overflow-y: auto;
        }
        :fullscreen h1 { font-size: 4em; }
        :fullscreen h2 { font-size: 3.2em; }
        :fullscreen h3 { font-size: 2.5em; }
        :fullscreen .content { font-size: 1.4em; }
        /* Webkit fullscreen support */
        :-webkit-full-screen .slide {
            width: 95%;
            max-width: none;
            min-height: 85vh;
            max-height: 95vh;
            padding: 30px 50px;
            overflow-y: auto;
        }
        :-webkit-full-screen h1 { font-size: 4em; }
        :-webkit-full-screen h2 { font-size: 3.2em; }
        :-webkit-full-screen h3 { font-size: 2.5em; }
        :-webkit-full-screen .content { font-size: 1.4em; }
    </style>
</head>
<body>
    <div class="main-content">
        <!-- Slayt 1: BaÅŸlÄ±k -->
        <div class="slide active">
            <h1>ğŸ”¬ AraÅŸtÄ±rma TasarÄ±mÄ±</h1>
            <h2>Spor ve Egzersiz Bilimlerinde</h2>
            <div class="content">
                <p style="text-align: center; font-size: 1.4em;"><span class="highlight">Hafta 5</span></p>
                <p style="text-align: center; margin-top: 30px;">Deneysel ve Deneysel Olmayan TasarÄ±mlar â€¢ GeÃ§erlik â€¢ GÃ¼venirlik â€¢ Etik</p>
            </div>
        </div>

        <!-- Slayt 2: AraÅŸtÄ±rma TasarÄ±mÄ±nÄ±n TanÄ±mÄ± -->
        <div class="slide">
            <h2>ğŸ“š AraÅŸtÄ±rma TasarÄ±mÄ± Nedir?</h2>
            <div class="content">
                <ul>
                    <li><strong>TanÄ±m:</strong> Bilimsel sorularÄ± yanÄ±tlamak iÃ§in kullanÄ±lan sistematik plan ve strateji</li>
                    <li><strong>AmaÃ§:</strong> GeÃ§erli ve gÃ¼venilir sonuÃ§lar elde etmek</li>
                    <li><strong>Kapsam:</strong> TÃ¼m araÅŸtÄ±rma sÃ¼recini yÃ¶nlendirir</li>
                    <li><strong>Ã–nem:</strong> Ã‡alÄ±ÅŸmanÄ±n kalitesini belirleyici faktÃ¶r</li>
                    <li><strong>SeÃ§im:</strong> AraÅŸtÄ±rma sorusuna ve amaca gÃ¶re belirlenir</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 3: Campbell ve Stanley SÄ±nÄ±flandÄ±rmasÄ± -->
        <div class="slide">
            <h2>ğŸ“– Campbell ve Stanley SÄ±nÄ±flandÄ±rmasÄ±</h2>
            <div class="content">
                <ul>
                    <li><strong>GerÃ§ek Deneysel (True Experimental):</strong>
                        <ul style="margin-top: 10px;">
                            <li>Randomizasyon mevcut</li>
                            <li>Kontrol grubu var</li>
                            <li>ManipÃ¼lasyon kontrolÃ¼</li>
                        </ul>
                    </li>
                    <li><strong>YarÄ± Deneysel (Quasi-Experimental):</strong>
                        <ul style="margin-top: 10px;">
                            <li>SÄ±nÄ±rlÄ± randomizasyon</li>
                            <li>DoÄŸal gruplar kullanÄ±mÄ±</li>
                            <li>ManipÃ¼lasyon var, kontrol sÄ±nÄ±rlÄ±</li>
                        </ul>
                    </li>
                    <li><strong>Ã–n-Deneysel (Pre-Experimental):</strong>
                        <ul style="margin-top: 10px;">
                            <li>Randomizasyon yok</li>
                            <li>Kontrol grubu sÄ±nÄ±rlÄ±/yok</li>
                            <li>Minimal manipÃ¼lasyon</li>
                        </ul>
                    </li>
                </ul>
            </div>
        </div>

        <!-- Slayt 4: Randomized Controlled Trial (RCT) -->
        <div class="slide">
            <h2>ğŸ¯ Randomized Controlled Trial (RCT)</h2>
            <div class="content">
                <ul>
                    <li><strong>AltÄ±n Standart:</strong> En yÃ¼ksek kanÄ±t dÃ¼zeyi saÄŸlar</li>
                    <li><strong>Randomizasyon:</strong> KatÄ±lÄ±mcÄ±lar rastgele gruplara atanÄ±r</li>
                    <li><strong>KÃ¶rleme:</strong> Tek-kÃ¶r, Ã§ift-kÃ¶r, Ã¼Ã§-kÃ¶r seÃ§enekleri</li>
                    <li><strong>Kontrol Grubu:</strong> Plasebo, standart tedavi veya kontrol</li>
                    <li><strong>CONSORT Rehberi:</strong> Raporlama standardÄ±</li>
                    <li><strong>KayÄ±t ZorunluluÄŸu:</strong> ClinicalTrials.gov gibi platformlar</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 5: FaktÃ¶riyel TasarÄ±mlar -->
        <div class="slide">
            <h2>ğŸ§© FaktÃ¶riyel TasarÄ±mlar</h2>
            <div class="content">
                <ul>
                    <li><strong>2Ã—2 FaktÃ¶riyel:</strong> Ä°ki faktÃ¶rÃ¼n ana ve etkileÅŸim etkilerini test eder</li>
                    <li><strong>Ana Etkiler:</strong> Her faktÃ¶rÃ¼n baÄŸÄ±msÄ±z etkisi</li>
                    <li><strong>EtkileÅŸim Etkisi:</strong> FaktÃ¶rlerin birlikte etkisi</li>
                    <li><strong>Avantajlar:</strong>
                        <ul style="margin-top: 10px;">
                            <li>Efficiency artÄ±ÅŸÄ±</li>
                            <li>Ã‡oklu hipotez testi</li>
                            <li>GerÃ§ek dÃ¼nya karmaÅŸÄ±klÄ±ÄŸÄ±nÄ± yansÄ±tÄ±r</li>
                        </ul>
                    </li>
                    <li><strong>Ã–rnek:</strong> Beslenme Ã— Antrenman tÃ¼rÃ¼ etkileÅŸimi</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 6: Crossover TasarÄ±mÄ± -->
        <div class="slide">
            <h2>ğŸ”„ Crossover TasarÄ±mÄ±</h2>
            <div class="content">
                <ul>
                    <li><strong>Within-Subject Design:</strong> Her katÄ±lÄ±mcÄ± kendi kontrolÃ¼</li>
                    <li><strong>Avantajlar:</strong>
                        <ul style="margin-top: 10px;">
                            <li>Bireysel farklar elimine edilir</li>
                            <li>Daha az katÄ±lÄ±mcÄ± gerekir</li>
                            <li>YÃ¼ksek istatistiksel gÃ¼Ã§</li>
                        </ul>
                    </li>
                    <li><strong>Washout Period:</strong> KalÄ±cÄ± etkileri Ã¶nler</li>
                    <li><strong>Counterbalancing:</strong> SÄ±ra etkilerini kontrol eder</li>
                    <li><strong>Uygun Durumlar:</strong> Beslenme, ergojenik yardÄ±mcÄ±lar</li>
                    <li><strong>Analiz:</strong> Mixed-effects modeller kullanÄ±lÄ±r</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 7: Kohort Ã‡alÄ±ÅŸmalarÄ± -->
        <div class="slide">
            <h2>ğŸ‘¥ Kohort Ã‡alÄ±ÅŸmalarÄ±</h2>
            <div class="content">
                <ul>
                    <li><strong>Prospektif Kohort:</strong> Zaman iÃ§inde ileriye doÄŸru takip</li>
                    <li><strong>Retrospektif Kohort:</strong> GeÃ§miÅŸ kayÄ±tlarÄ± geriye doÄŸru analiz</li>
                    <li><strong>Avantajlar:</strong>
                        <ul style="margin-top: 10px;">
                            <li>Temporal relationship kurulabilir</li>
                            <li>Ã‡oklu outcome incelenebilir</li>
                            <li>Ä°nsidans hesaplanabilir</li>
                        </ul>
                    </li>
                    <li><strong>Dezavantajlar:</strong> Zaman, maliyet, kayÄ±p takip</li>
                    <li><strong>Spor Ã–rneÄŸi:</strong> Uzun dÃ¶nem antrenman etkilerini izleme</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 8: Vaka-Kontrol Ã‡alÄ±ÅŸmalarÄ± -->
        <div class="slide">
            <h2>ğŸ” Vaka-Kontrol Ã‡alÄ±ÅŸmalarÄ±</h2>
            <div class="content">
                <ul>
                    <li><strong>Retrospektif TasarÄ±m:</strong> SonuÃ§tan nedene doÄŸru</li>
                    <li><strong>Vaka SeÃ§imi:</strong> Ä°lgilenilen outcome'u olan bireyler</li>
                    <li><strong>Kontrol SeÃ§imi:</strong> Outcome'u olmayan benzer bireyler</li>
                    <li><strong>Risk FaktÃ¶rÃ¼ Analizi:</strong> Odds ratio hesaplanÄ±r</li>
                    <li><strong>Avantajlar:</strong> HÄ±zlÄ±, ucuz, nadir hastalÄ±klar iÃ§in uygun</li>
                    <li><strong>Bias Riskleri:</strong> Selection bias, recall bias</li>
                    <li><strong>Spor Ã–rneÄŸi:</strong> Yaralanma risk faktÃ¶rlerini belirleme</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 9: Kesitsel Ã‡alÄ±ÅŸmalar -->
        <div class="slide">
            <h2>ğŸ“¸ Kesitsel Ã‡alÄ±ÅŸmalar</h2>
            <div class="content">
                <ul>
                    <li><strong>Snapshot YaklaÅŸÄ±mÄ±:</strong> Belirli bir zamandaki durum</li>
                    <li><strong>Prevalans Ã‡alÄ±ÅŸmasÄ±:</strong> HastalÄ±k/durum sÄ±klÄ±ÄŸÄ±nÄ± belirler</li>
                    <li><strong>HÄ±z ve Maliyet:</strong> En hÄ±zlÄ± ve ucuz yÃ¶ntem</li>
                    <li><strong>SÄ±nÄ±rlÄ±lÄ±klar:</strong>
                        <ul style="margin-top: 10px;">
                            <li>Nedensellik kurulamaz</li>
                            <li>Temporal relationship belirsiz</li>
                            <li>Survival bias riski</li>
                        </ul>
                    </li>
                    <li><strong>Spor Ã–rneÄŸi:</strong> SporcularÄ±n beslenme alÄ±ÅŸkanlÄ±klarÄ±</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 10: Meta-Analiz -->
        <div class="slide">
            <h2>ğŸ“Š Meta-Analiz</h2>
            <div class="content">
                <ul>
                    <li><strong>KanÄ±t Sentezi:</strong> Birden fazla Ã§alÄ±ÅŸmanÄ±n birleÅŸtirilmesi</li>
                    <li><strong>Etki BÃ¼yÃ¼klÃ¼ÄŸÃ¼:</strong> Cohen's d, Hedges' g hesaplanÄ±r</li>
                    <li><strong>Heterojenite:</strong> IÂ² istatistiÄŸi ile deÄŸerlendirilir</li>
                    <li><strong>Fixed vs Random Effects:</strong> Model seÃ§imi kritik</li>
                    <li><strong>Publication Bias:</strong> Funnel plot ile kontrol edilir</li>
                    <li><strong>PRISMA Rehberi:</strong> Sistematik derleme standardÄ±</li>
                    <li><strong>Cochrane Reviews:</strong> En yÃ¼ksek kalite standardÄ±</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 11: Karma YÃ¶ntem AraÅŸtÄ±rmalarÄ± -->
        <div class="slide">
            <h2>ğŸ”€ Karma YÃ¶ntem (Mixed Methods)</h2>
            <div class="content">
                <ul>
                    <li><strong>Explanatory Sequential:</strong> QUAN â†’ qual sÄ±rasÄ±</li>
                    <li><strong>Exploratory Sequential:</strong> QUAL â†’ quan sÄ±rasÄ±</li>
                    <li><strong>Concurrent Triangulation:</strong> EÅŸzamanlÄ± toplama</li>
                    <li><strong>Transformative Framework:</strong> Sosyal adalet odaklÄ±</li>
                    <li><strong>Avantajlar:</strong>
                        <ul style="margin-top: 10px;">
                            <li>KapsamlÄ± anlayÄ±ÅŸ</li>
                            <li>Ã‡apraz doÄŸrulama</li>
                            <li>Beklenmedik bulgularÄ± keÅŸfetme</li>
                        </ul>
                    </li>
                    <li><strong>Spor Ã–rneÄŸi:</strong> Performans + sporcu deneyimi analizi</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 12: Ä°Ã§ GeÃ§erlik -->
        <div class="slide">
            <h2>ğŸ¯ Ä°Ã§ GeÃ§erlik (Internal Validity)</h2>
            <div class="content">
                <ul>
                    <li><strong>TanÄ±m:</strong> Nedensel Ã§Ä±karÄ±mÄ±n doÄŸruluÄŸu</li>
                    <li><strong>Tarih Etkisi:</strong> DÄ±ÅŸ olaylarÄ±n mÃ¼dahalesi</li>
                    <li><strong>OlgunlaÅŸma:</strong> Zamanla doÄŸal deÄŸiÅŸimler</li>
                    <li><strong>Test Etkisi:</strong> Ã–n-testin son-testi etkilemesi</li>
                    <li><strong>Regresyon:</strong> Ekstrem skorlarÄ±n ortalamaya dÃ¶nÃ¼ÅŸÃ¼</li>
                    <li><strong>SeÃ§im Bias:</strong> Grup farklÄ±lÄ±klarÄ±</li>
                    <li><strong>KayÄ±p Takip:</strong> Differential dropout</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 13: DÄ±ÅŸ GeÃ§erlik -->
        <div class="slide">
            <h2>ğŸŒ DÄ±ÅŸ GeÃ§erlik (External Validity)</h2>
            <div class="content">
                <ul>
                    <li><strong>TanÄ±m:</strong> SonuÃ§larÄ±n genellenebilirliÄŸi</li>
                    <li><strong>Population Validity:</strong> DiÄŸer popÃ¼lasyonlara genelleme</li>
                    <li><strong>Ecological Validity:</strong> FarklÄ± ortamlara genelleme</li>
                    <li><strong>Temporal Validity:</strong> FarklÄ± zamanlara genelleme</li>
                    <li><strong>Treatment Validity:</strong> FarklÄ± mÃ¼dahale koÅŸullarÄ±na genelleme</li>
                    <li><strong>Trade-off:</strong> Ä°Ã§ ve dÄ±ÅŸ geÃ§erlik arasÄ±nda denge</li>
                    <li><strong>Replikasyon:</strong> GenellenebilirliÄŸin testi</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 14: YapÄ± GeÃ§erliÄŸi -->
        <div class="slide">
            <h2>ğŸ—ï¸ YapÄ± GeÃ§erliÄŸi (Construct Validity)</h2>
            <div class="content">
                <ul>
                    <li><strong>TanÄ±m:</strong> Teorik kavramlarÄ±n operasyonel tanÄ±mlarÄ±nÄ±n doÄŸruluÄŸu</li>
                    <li><strong>Convergent Validity:</strong> Ä°liÅŸkili yapÄ±larla pozitif korelasyon</li>
                    <li><strong>Discriminant Validity:</strong> Ä°liÅŸkisiz yapÄ±larla dÃ¼ÅŸÃ¼k korelasyon</li>
                    <li><strong>Face Validity:</strong> GÃ¶rÃ¼nÃ¼rdeki uygunluk</li>
                    <li><strong>Content Validity:</strong> Ä°Ã§erik alanÄ±nÄ± temsil etme</li>
                    <li><strong>Criterion Validity:</strong> DÄ±ÅŸ Ã¶lÃ§Ã¼tle uyumluluk</li>
                    <li><strong>Factor Analysis:</strong> YapÄ± doÄŸrulama yÃ¶ntemi</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 15: Ä°statistiksel SonuÃ§ GeÃ§erliÄŸi -->
        <div class="slide">
            <h2>ğŸ“ˆ Ä°statistiksel SonuÃ§ GeÃ§erliÄŸi</h2>
            <div class="content">
                <ul>
                    <li><strong>TanÄ±m:</strong> Ä°statistiksel Ã§Ä±karÄ±mlarÄ±n doÄŸruluÄŸu</li>
                    <li><strong>Type I Error (Î±):</strong> YanlÄ±ÅŸ pozitif, genellikle 0.05</li>
                    <li><strong>Type II Error (Î²):</strong> YanlÄ±ÅŸ negatif</li>
                    <li><strong>Statistical Power:</strong> 1-Î², genellikle >0.80 hedeflenir</li>
                    <li><strong>Effect Size:</strong> Pratik anlamlÄ±lÄ±k</li>
                    <li><strong>Sample Size:</strong> GÃ¼Ã§ analizine dayalÄ± hesaplama</li>
                    <li><strong>Assumptions:</strong> Test varsayÄ±mlarÄ±nÄ±n kontrolÃ¼</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 16: GÃ¼venirlik -->
        <div class="slide">
            <h2>ğŸ¯ GÃ¼venirlik (Reliability)</h2>
            <div class="content">
                <ul>
                    <li><strong>Test-Retest:</strong> Zaman iÃ§indeki tutarlÄ±lÄ±k</li>
                    <li><strong>Inter-rater:</strong> DeÄŸerlendiriciler arasÄ± uyumluluk</li>
                    <li><strong>Intra-rater:</strong> AynÄ± deÄŸerlendiricinin tutarlÄ±lÄ±ÄŸÄ±</li>
                    <li><strong>Internal Consistency:</strong> Cronbach's alpha (>0.70)</li>
                    <li><strong>Parallel Forms:</strong> EÅŸdeÄŸer formlar tutarlÄ±lÄ±ÄŸÄ±</li>
                    <li><strong>Split-Half:</strong> YarÄ±m bÃ¶lme gÃ¼venirliÄŸi</li>
                    <li><strong>ICC:</strong> Intraclass Correlation Coefficient</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 17: Ã–rneklem BÃ¼yÃ¼klÃ¼ÄŸÃ¼ -->
        <div class="slide">
            <h2>ğŸ“Š Ã–rneklem BÃ¼yÃ¼klÃ¼ÄŸÃ¼ ve GÃ¼Ã§ Analizi</h2>
            <div class="content">
                <ul>
                    <li><strong>A Priori:</strong> Ã‡alÄ±ÅŸma Ã¶ncesi hesaplama</li>
                    <li><strong>Post-hoc:</strong> Ã‡alÄ±ÅŸma sonrasÄ± gÃ¼Ã§ analizi</li>
                    <li><strong>Effect Size:</strong> Beklenen etki bÃ¼yÃ¼klÃ¼ÄŸÃ¼ tahmin</li>
                    <li><strong>Cohen's Benchmarks:</strong> KÃ¼Ã§Ã¼k (0.2), orta (0.5), bÃ¼yÃ¼k (0.8)</li>
                    <li><strong>G*Power:</strong> YaygÄ±n kullanÄ±lan yazÄ±lÄ±m</li>
                    <li><strong>Inflation Factors:</strong> Dropout, protocol deviation</li>
                    <li><strong>Feasibility:</strong> Pratik kÄ±sÄ±tlamalarÄ±n deÄŸerlendirilmesi</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 18: Randomizasyon YÃ¶ntemleri -->
        <div class="slide">
            <h2>ğŸ² Randomizasyon Teknikleri</h2>
            <div class="content">
                <ul>
                    <li><strong>Simple Randomization:</strong> Basit rastgele atama</li>
                    <li><strong>Block Randomization:</strong> Blok iÃ§i denge saÄŸlama</li>
                    <li><strong>Stratified Randomization:</strong> Ã–nemli deÄŸiÅŸkenlere gÃ¶re tabakalaÅŸtÄ±rma</li>
                    <li><strong>Minimization:</strong> Dinamik dengeleme</li>
                    <li><strong>Cluster Randomization:</strong> Grup bazlÄ± atama</li>
                    <li><strong>Allocation Concealment:</strong> Atama gizliliÄŸi</li>
                    <li><strong>SNOSE:</strong> Sequentially Numbered Opaque Sealed Envelopes</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 19: KÃ¶rleme Teknikleri -->
        <div class="slide">
            <h2>ğŸ‘ï¸ KÃ¶rleme (Blinding) Stratejileri</h2>
            <div class="content">
                <ul>
                    <li><strong>Tek KÃ¶r:</strong> KatÄ±lÄ±mcÄ± bilmiyor</li>
                    <li><strong>Ã‡ift KÃ¶r:</strong> KatÄ±lÄ±mcÄ± ve araÅŸtÄ±rmacÄ± bilmiyor</li>
                    <li><strong>ÃœÃ§ KÃ¶r:</strong> Veri analizci de bilmiyor</li>
                    <li><strong>Plasebo KontrolÃ¼:</strong> Inactive treatment</li>
                    <li><strong>Sham Procedures:</strong> Sahte mÃ¼dahale</li>
                    <li><strong>Blinding Assessment:</strong> KÃ¶rleme baÅŸarÄ±sÄ±nÄ±n deÄŸerlendirilmesi</li>
                    <li><strong>Performance Bias:</strong> KÃ¶rleme yokluÄŸunun etkisi</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 20: AraÅŸtÄ±rma EtiÄŸi -->
        <div class="slide">
            <h2>âš–ï¸ AraÅŸtÄ±rma EtiÄŸi</h2>
            <div class="content">
                <ul>
                    <li><strong>Belmont Ä°lkeleri:</strong> Respect, Beneficence, Justice</li>
                    <li><strong>Informed Consent:</strong> BilgilendirilmiÅŸ onam sÃ¼reci</li>
                    <li><strong>Risk-Benefit Analizi:</strong> Etik deÄŸerlendirmenin temeli</li>
                    <li><strong>Vulnerable Populations:</strong> Ã–zel koruma gerektiren gruplar</li>
                    <li><strong>IRB/Ethics Committee:</strong> BaÄŸÄ±msÄ±z etik kurul onayÄ±</li>
                    <li><strong>GDPR/KVKK UyumluluÄŸu:</strong> Veri koruma gereksinimleri</li>
                    <li><strong>Helsinki Declaration:</strong> TÄ±bbi araÅŸtÄ±rmalarda etik</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 21: Spor Bilimlerinde Ã–zel Etik Durumlar -->
        <div class="slide">
            <h2>ğŸƒâ€â™‚ï¸ Spor Bilimlerinde Etik</h2>
            <div class="content">
                <ul>
                    <li><strong>Ã‡ocuk Sporcular:</strong> Ebeveyn onayÄ± + child assent</li>
                    <li><strong>Elite Sporcular:</strong> Performans baskÄ±sÄ±, career impact</li>
                    <li><strong>Yaralanma Riski:</strong> Minimal risk prensibinin uygulanmasÄ±</li>
                    <li><strong>Doping Research:</strong> YasaklÄ± madde kullanÄ±m etiÄŸi</li>
                    <li><strong>TakÄ±m Dinamikleri:</strong> Bireysel vs kolektif Ã§Ä±karlar</li>
                    <li><strong>Gender Research:</strong> Hormonal dÃ¶ngÃ¼ler ve mahremiyet</li>
                    <li><strong>Performance Enhancement:</strong> DoÄŸal geliÅŸim sÄ±nÄ±rlarÄ±</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 22: Veri Analizi Stratejileri -->
        <div class="slide">
            <h2>ğŸ“ˆ Veri Analizi YaklaÅŸÄ±mlarÄ±</h2>
            <div class="content">
                <ul>
                    <li><strong>Intention-to-Treat:</strong> Orijinal atamaya gÃ¶re analiz</li>
                    <li><strong>Per-Protocol:</strong> Protokole uyanlara gÃ¶re analiz</li>
                    <li><strong>Missing Data:</strong> LOCF, MICE, Multiple Imputation</li>
                    <li><strong>Interim Analysis:</strong> Ara analiz ve durdurma kurallarÄ±</li>
                    <li><strong>Multiple Comparisons:</strong> Bonferroni, FDR dÃ¼zeltmeleri</li>
                    <li><strong>Sensitivity Analysis:</strong> SonuÃ§larÄ±n gÃ¼venilirlik testi</li>
                    <li><strong>Bayesian Methods:</strong> Prior bilgi entegrasyonu</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 23: Raporlama StandartlarÄ± -->
        <div class="slide">
            <h2>ğŸ“ Bilimsel Raporlama Rehberleri</h2>
            <div class="content">
                <ul>
                    <li><strong>CONSORT:</strong> Randomize kontrollÃ¼ Ã§alÄ±ÅŸmalar</li>
                    <li><strong>STROBE:</strong> GÃ¶zlemsel Ã§alÄ±ÅŸmalar</li>
                    <li><strong>PRISMA:</strong> Sistematik derleme ve meta-analizler</li>
                    <li><strong>SPIRIT:</strong> Ã‡alÄ±ÅŸma protokolleri</li>
                    <li><strong>COREQ:</strong> Nitel araÅŸtÄ±rma</li>
                    <li><strong>STARD:</strong> Diagnostik accuracy Ã§alÄ±ÅŸmalarÄ±</li>
                    <li><strong>EQUATOR Network:</strong> Raporlama rehberleri merkezi</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 24: Modern Metodolojik GeliÅŸmeler -->
        <div class="slide">
            <h2>ğŸ”¬ Ã‡aÄŸdaÅŸ AraÅŸtÄ±rma YÃ¶nelimleri</h2>
            <div class="content">
                <ul>
                    <li><strong>Precision Medicine:</strong> KiÅŸiselleÅŸtirilmiÅŸ tedavi yaklaÅŸÄ±mlarÄ±</li>
                    <li><strong>Big Data Analytics:</strong> BÃ¼yÃ¼k veri setlerinin analizi</li>
                    <li><strong>Machine Learning:</strong> Yapay zeka destekli araÅŸtÄ±rma</li>
                    <li><strong>Wearable Technology:</strong> SÃ¼rekli monitÃ¶rizasyon imkanlarÄ±</li>
                    <li><strong>Digital Biomarkers:</strong> Dijital saÄŸlÄ±k gÃ¶stergeleri</li>
                    <li><strong>Adaptive Designs:</strong> Esnek Ã§alÄ±ÅŸma tasarÄ±mlarÄ±</li>
                    <li><strong>Real-World Evidence:</strong> GerÃ§ek dÃ¼nya verileri</li>
                </ul>
            </div>
        </div>

        <!-- Slayt 25: SonuÃ§ ve Ã–neriler -->
        <div class="slide">
            <h2>ğŸ¯ Ã–zet ve Gelecek YÃ¶nelimleri</h2>
            <div class="content">
                <ul>
                    <li><strong>TasarÄ±m SeÃ§imi:</strong> AraÅŸtÄ±rma sorusuna uygun metodoloji</li>
                    <li><strong>GeÃ§erlik Dengesi:</strong> Ä°Ã§ ve dÄ±ÅŸ geÃ§erlik optimizasyonu</li>
                    <li><strong>Etik Ã–ncelik:</strong> Ä°nsan haklarÄ±nÄ±n korunmasÄ±</li>
                    <li><strong>Open Science:</strong> ÅeffaflÄ±k ve reproducibility</li>
                    <li><strong>Multidisciplinary:</strong> Disiplinler arasÄ± iÅŸbirliÄŸi</li>
                    <li><strong>Technology Integration:</strong> Teknolojik yeniliklerin adaptasyonu</li>
                    <li><strong>Global Standards:</strong> UluslararasÄ± standartlara uyum</li>
                </ul>
                <div class="formula">
                    <strong>Gelecek Hafta:</strong> Ã–rneklem ve Evren
                </div>
            </div>
        </div>
    </div>

    <!-- Sidebar Content -->
    <div class="sidebar" id="sidebar-1">
        <h3>ğŸ”¬ AraÅŸtÄ±rma TasarÄ±mÄ±: KapsamlÄ± GiriÅŸ</h3>
        <h4>ğŸ“š AraÅŸtÄ±rma TasarÄ±mÄ±nÄ±n Tarihsel GeliÅŸimi</h4>
        <p>Modern araÅŸtÄ±rma tasarÄ±mÄ± kavramÄ±, 20. yÃ¼zyÄ±lÄ±n baÅŸlarÄ±nda Ronald Fisher'Ä±n tarÄ±msal deneylerle baÅŸlamÄ±ÅŸtÄ±r. Fisher'Ä±n "The Design of Experiments" (1935) kitabÄ±, randomizasyon, replikasyon ve yerel kontrol ilkelerini sistematize etmiÅŸtir.</p>

        <p><strong>Campbell ve Stanley'in KatkÄ±larÄ± (1963):</strong> "Experimental and Quasi-Experimental Designs for Research" Ã§alÄ±ÅŸmasÄ±, geÃ§erlik tÃ¼rlerini (iÃ§, dÄ±ÅŸ geÃ§erlik) tanÄ±mlamÄ±ÅŸ ve deneysel tasarÄ±m sÄ±nÄ±flandÄ±rmasÄ±nÄ±n temellerini atmÄ±ÅŸtÄ±r.</p>

        <h4>ğŸ¯ Spor Bilimlerinde AraÅŸtÄ±rma TasarÄ±mÄ±</h4>
        <p>Spor bilimleri, multidisipliner doÄŸasÄ± gereÄŸi farklÄ± araÅŸtÄ±rma paradigmalarÄ±nÄ± bir araya getirir:</p>
        <ul>
            <li><strong>Fizyolojik AraÅŸtÄ±rmalar:</strong> KontrollÃ¼ laboratuvar koÅŸullarÄ±nda RCT tasarÄ±mlarÄ±</li>
            <li><strong>Performans AraÅŸtÄ±rmalarÄ±:</strong> Sahada uygulanan yarÄ±-deneysel tasarÄ±mlar</li>
            <li><strong>Psikolojik AraÅŸtÄ±rmalar:</strong> Kesitsel ve boylamsal gÃ¶zlemsel tasarÄ±mlar</li>
            <li><strong>Epidemiyolojik AraÅŸtÄ±rmalar:</strong> BÃ¼yÃ¼k kohort Ã§alÄ±ÅŸmalarÄ±</li>
        </ul>

        <h4>ğŸ”„ Paradigmatik Ã‡erÃ§eveler</h4>
        <p><strong>Pozitivist Paradigma:</strong> Objektif gerÃ§eklik varsayÄ±mÄ±, Ã¶lÃ§Ã¼lebilir fenomenler, hipotez-test yaklaÅŸÄ±mÄ±. Spor bilimlerinde laboratuvar testleri, fizyolojik Ã¶lÃ§Ã¼mler bu paradigmaya dayanÄ±r.</p>

        <p><strong>Post-pozitivist Paradigma:</strong> EleÅŸtirel realist yaklaÅŸÄ±m, multiple perspektifler, triangulation. Karma yÃ¶ntem araÅŸtÄ±rmalarÄ±nÄ±n teorik temeli.</p>

        <p><strong>YapÄ±landÄ±rmacÄ± Paradigma:</strong> Sosyal gerÃ§eklik inÅŸasÄ±, subjektif deneyimler, yorumlayÄ±cÄ± yaklaÅŸÄ±m. Sporcu deneyimleri, takÄ±m kÃ¼ltÃ¼rÃ¼ araÅŸtÄ±rmalarÄ±.</p>
    </div>

    <div class="sidebar" id="sidebar-2">
        <h3>ğŸ“š AraÅŸtÄ±rma TasarÄ±mÄ±: Temel TanÄ±m ve BileÅŸenler</h3>
        <h4>ğŸ” Sistematik Planlama SÃ¼reci</h4>
        <p>AraÅŸtÄ±rma tasarÄ±mÄ±, bilimsel sorgulamada kullanÄ±lan sistematik yaklaÅŸÄ±mlarÄ±n toplamÄ±dÄ±r. Bu sÃ¼reÃ§, Kerlinger ve Lee'nin (2000) tanÄ±mÄ±yla "araÅŸtÄ±rma sorusuna yanÄ±t aramak iÃ§in kullanÄ±lan conditions ve procedures'larÄ±n planÄ±"dÄ±r.</p>

        <p><strong>Temel BileÅŸenler:</strong></p>
        <ul>
            <li><strong>Epistemolojik Temel:</strong> Bilgi edinme yaklaÅŸÄ±mÄ±</li>
            <li><strong>Teorik Ã‡erÃ§eve:</strong> Kavramsal model</li>
            <li><strong>Metodolojik SeÃ§im:</strong> Veri toplama stratejisi</li>
            <li><strong>Analitik Plan:</strong> Veri analiz stratejisi</li>
            <li><strong>GeÃ§erlik KontrolÃ¼:</strong> Kalite gÃ¼vence mekanizmalarÄ±</li>
        </ul>

        <h4>ğŸ¯ TasarÄ±m SeÃ§im Kriterleri</h4>
        <p><strong>AraÅŸtÄ±rma Sorusunun TÃ¼rÃ¼:</strong></p>
        <ul>
            <li><strong>TanÄ±mlayÄ±cÄ±:</strong> "Nedir?" sorularÄ± â†’ Kesitsel, gÃ¶zlemsel tasarÄ±mlar</li>
            <li><strong>Ä°liÅŸkisel:</strong> "Ä°liÅŸki var mÄ±?" â†’ Korelasyonel, kohort tasarÄ±mlarÄ±</li>
            <li><strong>Nedensel:</strong> "Neden oluyor?" â†’ RCT, deneysel tasarÄ±mlar</li>
            <li><strong>KarÅŸÄ±laÅŸtÄ±rmalÄ±:</strong> "Hangisi daha iyi?" â†’ KontrollÃ¼ deneyler</li>
        </ul>

        <h4>ğŸ“Š Spor Bilimlerinde TasarÄ±m SeÃ§imi</h4>
        <p><strong>Antrenman Etkisi AraÅŸtÄ±rmalarÄ±:</strong> Pre-post kontrol grubu tasarÄ±mÄ± veya Ã§aprazlama tasarÄ±mÄ± tercih edilir. TaÅŸÄ±nma etkisi'i minimize etmek iÃ§in temizlenme sÃ¼resi kritik.</p>

        <p><strong>Beslenme AraÅŸtÄ±rmalarÄ±:</strong> Ã‡ift kÃ¶r plasebo kontrollÃ¼ denemeler altÄ±n standart. Uyum izleme iÃ§in besin gÃ¼nlÃ¼ÄŸÃ¼'ler ve biyobelirteÃ§ler kullanÄ±lÄ±r.</p>

        <p><strong>Yaralanma AraÅŸtÄ±rmalarÄ±:</strong> Prospektif kohort tasarÄ±mlarÄ± tercih edilir. Exposure time hesaplamasÄ± (athlete exposure hours) standardize edilmiÅŸtir.</p>
    </div>

    <div class="sidebar" id="sidebar-3">
        <h3>ğŸ“– Campbell ve Stanley: Klasik SÄ±nÄ±flandÄ±rma</h3>
        <h4>ğŸ›ï¸ Tarihsel Ã–nemi</h4>
        <p>Donald Campbell ve Julian Stanley'in 1963 Ã§alÄ±ÅŸmasÄ±, araÅŸtÄ±rma tasarÄ±mÄ± metodolojisinin temel taÅŸlarÄ±ndan biridir. Bu Ã§alÄ±ÅŸma, deneysel tasarÄ±mlarÄ± sistematik olarak sÄ±nÄ±flandÄ±ran ilk kapsamlÄ± yaklaÅŸÄ±mdÄ±r.</p>

        <h4>ğŸ¯ GerÃ§ek Deneysel TasarÄ±mlar</h4>
        <p><strong>Randomized Post-test Only Control Group:</strong></p>
        <ul>
            <li><strong>Notasyon:</strong> R X Oâ‚ / R - Oâ‚‚</li>
            <li><strong>Avantaj:</strong> Pre-test sensitization yok</li>
            <li><strong>Dezavantaj:</strong> Baseline eÅŸitliÄŸi bilinmiyor</li>
            <li><strong>Spor Ã–rneÄŸi:</strong> Yeni antrenman programÄ±nÄ±n performansa etkisi</li>
        </ul>

        <p><strong>Pre-test Post-test Control Group:</strong></p>
        <ul>
            <li><strong>Notasyon:</strong> R Oâ‚ X Oâ‚‚ / R Oâ‚ƒ - Oâ‚„</li>
            <li><strong>Avantaj:</strong> Change score analizi yapÄ±labilir</li>
            <li><strong>Dezavantaj:</strong> Test-retest sensitization</li>
            <li><strong>Analiz:</strong> (Oâ‚‚-Oâ‚) - (Oâ‚„-Oâ‚ƒ)</li>
        </ul>

        <p><strong>Solomon Four-Group Design:</strong> En gÃ¼Ã§lÃ¼ tasarÄ±m, hem pre-test etkisini kontrol eder hem de treatment effect'i test eder.</p>

        <h4>ğŸ”„ YarÄ± Deneysel TasarÄ±mlar</h4>
        <p><strong>EÅŸdeÄŸer Olmayan Kontrol Grubu TasarÄ±mÄ±:</strong> Spor bilimlerinde en yaygÄ±n kullanÄ±lan tasarÄ±m. Intact groups (takÄ±mlar) kullanÄ±lÄ±r, randomizasyon yoktur.</p>

        <p><strong>Time Series Design:</strong> MÃ¼dahale Ã¶ncesi ve sonrasÄ± Ã§oklu Ã¶lÃ§Ã¼mler. Trend analizi ile mÃ¼dahale etkisi deÄŸerlendirilir.</p>

        <h4>ğŸ“Š Ã–n-Deneysel TasarÄ±mlar</h4>
        <p>Bu tasarÄ±mlar gÃ¼Ã§lÃ¼ Ã§Ä±karÄ±mlara izin vermez ancak pilot Ã§alÄ±ÅŸmalar iÃ§in kullanÄ±ÅŸlÄ±dÄ±r:</p>
        <ul>
            <li><strong>One-shot Case Study:</strong> X O (sadece mÃ¼dahale sonrasÄ± Ã¶lÃ§Ã¼m)</li>
            <li><strong>One Group Pre-test Post-test:</strong> Oâ‚ X Oâ‚‚</li>
        </ul>
    </div>

    <div class="sidebar" id="sidebar-4">
        <h3>ğŸ¯ Randomized Controlled Trial: AltÄ±n Standart</h3>
        <h4>ğŸ† RCT'nin ÃœstÃ¼nlÃ¼ÄŸÃ¼</h4>
        <p>RCT, nedensel Ã§Ä±karÄ±m yapabilmek iÃ§in tasarlanmÄ±ÅŸ en gÃ¼Ã§lÃ¼ araÅŸtÄ±rma tasarÄ±mÄ±dÄ±r. Hill'in (1965) nedensellik kriterleri Ã§erÃ§evesinde, RCT temporal sequence, dose-response relationship ve consistency kriterlerini en iyi ÅŸekilde saÄŸlar.</p>

        <h4>ğŸ² Randomizasyon Teorisi</h4>
        <p><strong>Fisher'Ä±n Randomizasyon Ä°lkesi:</strong> Her katÄ±lÄ±mcÄ±nÄ±n her gruba eÅŸit olasÄ±lÄ±kla atanmasÄ±, bilinen ve bilinmeyen tÃ¼m karÄ±ÅŸtÄ±rÄ±cÄ± deÄŸiÅŸken'larÄ± dengeler. Bu, seÃ§im yanlÄ±lÄ±ÄŸÄ±'Ä±n elimine edilmesini saÄŸlar.</p>

        <p><strong>Randomizasyon TÃ¼rleri:</strong></p>
        <ul>
            <li><strong>Simple:</strong> Coin toss, random number table</li>
            <li><strong>Blocked:</strong> Belirli blok boyutlarÄ±nda denge</li>
            <li><strong>Stratified:</strong> Ã–nemli covariatelara gÃ¶re tabakalaÅŸtÄ±rma</li>
            <li><strong>Adaptive:</strong> Intermediate outcome'a gÃ¶re ayarlama</li>
        </ul>

        <h4>ğŸ‘ï¸ KÃ¶rleme Stratejileri</h4>
        <p><strong>Performance Bias KontrolÃ¼:</strong> KatÄ±lÄ±mcÄ± ve araÅŸtÄ±rmacÄ±nÄ±n beklenti etkilerini elimine eder.</p>

        <p><strong>Detection Bias KontrolÃ¼:</strong> Outcome assessor'Ä±n Ã¶nyargÄ±sÄ±nÄ± Ã¶nler.</p>

        <p><strong>Spor Bilimlerinde KÃ¶rleme ZorluklarÄ±:</strong> Egzersiz mÃ¼dahalelerinde gerÃ§ek kÃ¶rleme zor. Sham exercise, dikkat kontrol gruplarÄ± kullanÄ±labilir.</p>

        <h4>ğŸ“‹ CONSORT Rehberi</h4>
        <p>CONsolidated Standards of Reporting Trials (CONSORT) 2010, RCT raporlamasÄ±nÄ±n standart formatÄ±dÄ±r:</p>
        <ul>
            <li><strong>Flow Diagram:</strong> Participant flow'un gÃ¶rsel sunumu</li>
            <li><strong>25 Maddelik Checklist:</strong> Raporlama gereksinimleri</li>
            <li><strong>Extensions:</strong> Cluster trials, non-inferiority, pilot studies</li>
        </ul>

        <h4>ğŸŒ Trial Registration</h4>
        <p>WHO Trial Registration Data Set: Primary registry'lerde prospektif kayÄ±t zorunluluÄŸu. Publication bias'Ä± Ã¶nleme, selective reporting'i engelleme amacÄ±.</p>
    </div>

    <div class="sidebar" id="sidebar-5">
        <h3>ğŸ§© FaktÃ¶riyel TasarÄ±mlar: EtkileÅŸim Analizi</h3>
        <h4>ğŸ“Š FaktÃ¶riyel TasarÄ±m Teorisi</h4>
        <p>FaktÃ¶riyel tasarÄ±mlar, R.A. Fisher'Ä±n tarÄ±msal araÅŸtÄ±rmalarÄ±ndan geliÅŸmiÅŸtir. Temel prensibi, birden fazla faktÃ¶rÃ¼n etkilerini aynÄ± anda ve efficiently test etmektir. 2Ã—2 faktÃ¶riyel tasarÄ±m, iki faktÃ¶rÃ¼n her birinin iki dÃ¼zeyini test eder.</p>

        <p><strong>Ana Etki (Main Effect):</strong> Bir faktÃ¶rÃ¼n diÄŸer faktÃ¶rlerden baÄŸÄ±msÄ±z olarak baÄŸÄ±mlÄ± deÄŸiÅŸken Ã¼zerindeki etkisi. Marginal means'lerin karÅŸÄ±laÅŸtÄ±rÄ±lmasÄ± ile hesaplanÄ±r.</p>

        <p><strong>EtkileÅŸim Etkisi (Interaction Effect):</strong> Ä°ki faktÃ¶rÃ¼n birlikte yarattÄ±ÄŸÄ± sinerjik veya antagonistik etki. Non-additivity durumunu gÃ¶sterir.</p>

        <h4>ğŸ”¢ Matematiksel Model</h4>
        <p><strong>Ä°ki-faktÃ¶rlÃ¼ ANOVA Modeli:</strong></p>
        <p>Yáµ¢â±¼â‚– = Î¼ + Î±áµ¢ + Î²â±¼ + (Î±Î²)áµ¢â±¼ + Îµáµ¢â±¼â‚–</p>
        <ul>
            <li>Î¼ = genel ortalama</li>
            <li>Î±áµ¢ = A faktÃ¶rÃ¼nÃ¼n ana etkisi</li>
            <li>Î²â±¼ = B faktÃ¶rÃ¼nÃ¼n ana etkisi</li>
            <li>(Î±Î²)áµ¢â±¼ = etkileÅŸim etkisi</li>
            <li>Îµáµ¢â±¼â‚– = hata terimi</li>
        </ul>

        <h4>ğŸƒâ€â™‚ï¸ Spor Bilimlerinde FaktÃ¶riyel TasarÄ±m Ã–rnekleri</h4>
        <p><strong>Beslenme Ã— Antrenman EtkileÅŸimi:</strong> Protein takviyesi (var/yok) Ã— Antrenman tÃ¼rÃ¼ (kuvvet/dayanÄ±klÄ±lÄ±k) faktÃ¶riyel tasarÄ±mÄ±nda, protein takviyesinin etkisi antrenman tÃ¼rÃ¼ne gÃ¶re farklÄ±lÄ±k gÃ¶sterebilir.</p>

        <p><strong>Cinsiyet Ã— YaÅŸ EtkileÅŸimi:</strong> Antrenman programÄ±nÄ±n etkisi, cinsiyet ve yaÅŸ gruplarÄ±na gÃ¶re farklÄ± pattern gÃ¶sterebilir. Bu durum personalized training programlarÄ±nÄ±n temelini oluÅŸturur.</p>

        <h4>ğŸ“ˆ Etki BÃ¼yÃ¼klÃ¼ÄŸÃ¼ HesaplamasÄ±</h4>
        <p><strong>Partial Eta Squared (Î·pÂ²):</strong> FaktÃ¶riyel ANOVA'da effect size hesaplamasÄ±:</p>
        <p>Î·pÂ² = SS_effect / (SS_effect + SS_error)</p>
        <p>Cohen'in benchmark'larÄ±: kÃ¼Ã§Ã¼k (0.01), orta (0.06), bÃ¼yÃ¼k (0.14)</p>

        <h4>âš ï¸ VarsayÄ±mlar ve SÄ±nÄ±rlÄ±lÄ±klar</h4>
        <p>FaktÃ¶riyel ANOVA varsayÄ±mlarÄ±: normallik, varyans homojenliÄŸi, baÄŸÄ±msÄ±zlÄ±k. Box's M testi varyans-kovaryans matrislerinin homojenliÄŸini test eder. Sphericity varsayÄ±mÄ± repeated measures faktÃ¶riyel iÃ§in geÃ§erlidir.</p>
    </div>

    <div class="sidebar" id="sidebar-6">
        <h3>ğŸ”„ Crossover TasarÄ±mlarÄ±: Within-Subject Efficiency</h3>
        <h4>ğŸ¯ Crossover TasarÄ±mÄ±n Teorik Temelleri</h4>
        <p>Crossover tasarÄ±mlarÄ±, 1920'lerde tarÄ±msal araÅŸtÄ±rmalarda geliÅŸtirilmiÅŸtir. Temel prensibi, her deneysel birimin (katÄ±lÄ±mcÄ±nÄ±n) kendi kontrolÃ¼ olmasÄ±dÄ±r. Bu, denekler arasÄ± deÄŸiÅŸkenlik'yi elimine ederek istatistiksel gÃ¼Ã§'Ä± Ã¶nemli Ã¶lÃ§Ã¼de artÄ±rÄ±r.</p>

        <p><strong>AB/BA Crossover TasarÄ±mÄ±:</strong> En basit crossover tasarÄ±m. Grup 1: Aâ†’B, Grup 2: Bâ†’A sequence'Ä±nÄ± takip eder. Period effect ve treatmentÃ—period interaction kontrol edilir.</p>

        <h4>â±ï¸ Washout Period HesaplamasÄ±</h4>
        <p><strong>Pharmacokinetic YaklaÅŸÄ±m:</strong> Washout period, aktif maddenin eliminasyon yarÄ±-Ã¶mrÃ¼nÃ¼n 5-7 katÄ± kadar olmalÄ±dÄ±r. Spor beslenme araÅŸtÄ±rmalarÄ±nda bu sÃ¼re genellikle 1-2 hafta arasÄ±dÄ±r.</p>

        <p><strong>Physiological Recovery:</strong> Antrenman mÃ¼dahalelerinde, fizyolojik adaptasyonlarÄ±n baseline'a dÃ¶nmesi iÃ§in gerekli sÃ¼re. VOâ‚‚max deÄŸiÅŸiklikleri iÃ§in 3-4 hafta, kuvvet adaptasyonlarÄ± iÃ§in 2-3 hafta gereklidir.</p>

        <h4>ğŸ² Counterbalancing Stratejileri</h4>
        <p><strong>Simple Counterbalancing:</strong> Treatment'larÄ± yarÄ±sÄ± Aâ†’B, yarÄ±sÄ± Bâ†’A sÄ±rasÄ±nda alÄ±r.</p>
        <p><strong>Complete Counterbalancing:</strong> TÃ¼m olasÄ± sequence'lar kullanÄ±lÄ±r. 3 treatment iÃ§in 3! = 6 farklÄ± sequence.</p>
        <p><strong>Latin Kare TasarÄ±mÄ±:</strong> nÃ—n kare tasarÄ±m, her treatment her position'da bir kez gÃ¶rÃ¼nÃ¼r. Balanced incomplete block design alternatifi.</p>

        <h4>ğŸ“Š Ä°statistiksel Analiz YaklaÅŸÄ±mlarÄ±</h4>
        <p><strong>Mixed-Effects Modeling:</strong> Crossover analizinin modern yaklaÅŸÄ±mÄ±. Fixed effects: treatment, period, sequence. Random effects: subject.</p>

        <p><strong>Carryover Effect Testi:</strong> First period'un analizi ile carryover varlÄ±ÄŸÄ± test edilir. Significance durumunda paralel group analysis yapÄ±lÄ±r.</p>

        <h4>ğŸ‹ï¸â€â™€ï¸ Spor Bilimlerinde Crossover UygulamalarÄ±</h4>
        <p><strong>Ergojenik YardÄ±mcÄ±lar:</strong> Kafein, kreatin, beta-alanin gibi supplementlarÄ±n akut etkilerini test etmek iÃ§in ideal. Plasebo kontrol ile double-blind crossover tasarÄ±m altÄ±n standart.</p>

        <p><strong>Beslenme Timing:</strong> Pre-exercise, during-exercise, post-exercise beslenme stratejilerinin karÅŸÄ±laÅŸtÄ±rÄ±lmasÄ±. Glycogen depletion protocols ile standardize edilir.</p>
    </div>

    <div class="sidebar" id="sidebar-7">
        <h3>ğŸ‘¥ Kohort Ã‡alÄ±ÅŸmalarÄ±: Longitudinal Takip</h3>
        <h4>ğŸ“š Kohort Methodology'sinin TarihÃ§esi</h4>
        <p>Kohort Ã§alÄ±ÅŸmalarÄ±, epidemiyolojinin temel taÅŸlarÄ±ndan biridir. "Cohort" kelimesi Latince'den gelir ve Roma ordusundaki 600 kiÅŸilik askeri birimi ifade eder. Modern epidemiyolojide, ortak Ã¶zellikleri paylaÅŸan bireylerin gruplarÄ±nÄ± tanÄ±mlar.</p>

        <p><strong>Framingham Heart Study (1948):</strong> En Ã¼nlÃ¼ prospektif kohort Ã§alÄ±ÅŸmasÄ±. Cardiovascular risk faktÃ¶rlerini 70+ yÄ±ldÄ±r takip etmektedir. Spor bilimlerinde benzer uzun dÃ¶nem Ã§alÄ±ÅŸmalara model oluÅŸturmuÅŸtur.</p>

        <h4>â­ï¸ Prospektif vs Retrospektif Kohort</h4>
        <p><strong>Prospektif Kohort AvantajlarÄ±:</strong></p>
        <ul>
            <li>Temporal sequence kesin olarak kurulabilir</li>
            <li>Exposure Ã¶lÃ§Ã¼mÃ¼ objective ve prospective</li>
            <li>Multiple outcome'lar incelenebilir</li>
            <li>Incidence rate hesaplanabilir</li>
        </ul>

        <p><strong>Retrospektif Kohort SÄ±nÄ±rlÄ±lÄ±klarÄ±:</strong></p>
        <ul>
            <li>Information bias riski yÃ¼ksek</li>
            <li>Confounding control sÄ±nÄ±rlÄ±</li>
            <li>Missing data problemi yaygÄ±n</li>
            <li>Selection bias potansiyeli</li>
        </ul>

        <h4>ğŸ“Š Survival Analysis ve Cox Regression</h4>
        <p><strong>Kaplan-Meier Survival Curves:</strong> Time-to-event analizlerinde kullanÄ±lÄ±r. Spor bilimlerinde injury-free survival, career longevity analizlerinde uygulanÄ±r.</p>

        <p><strong>Cox Proportional Hazards Model:</strong></p>
        <p>h(t|x) = hâ‚€(t) Ã— exp(Î²â‚xâ‚ + Î²â‚‚xâ‚‚ + ... + Î²â‚šxâ‚š)</p>
        <p>Hazard ratio'larÄ± risk faktÃ¶rlerinin strength'ini gÃ¶sterir.</p>

        <h4>ğŸƒâ€â™‚ï¸ Spor Epidemiyolojisi Kohort Ã–rnekleri</h4>
        <p><strong>NFL Concussion Study:</strong> Amerikan futbol oyuncularÄ±nda kafa travmasÄ± ve uzun dÃ¶nem nÃ¶rolojik etkilerin prospektif takibi. Chronic traumatic encephalopathy (CTE) risk faktÃ¶rlerini belirlemiÅŸtir.</p>

        <p><strong>Runner's Health Study:</strong> KoÅŸucularÄ±n kardiyovaskÃ¼ler saÄŸlÄ±k outcomes'larÄ±nÄ±n 20+ yÄ±llÄ±k takibi. Exercise volume ve mortality arasÄ±ndaki U-shaped relationship'i gÃ¶stermiÅŸtir.</p>

        <h4>âš ï¸ Loss to Follow-up ve Missing Data</h4>
        <p>Kohort Ã§alÄ±ÅŸmalarÄ±nÄ±n en Ã¶nemli sorunu dropout'tur. >20% kayÄ±p, Ã§alÄ±ÅŸmanÄ±n geÃ§erliliÄŸini tehdit eder. Multiple imputation, inverse probability weighting gibi advanced techniques kullanÄ±lÄ±r.</p>
    </div>

    <div class="sidebar" id="sidebar-8">
        <h3>ğŸ” Vaka-Kontrol Ã‡alÄ±ÅŸmalarÄ±: Retrospektif YaklaÅŸÄ±m</h3>
        <h4>ğŸ¯ Case-Control Design Metodolojisi</h4>
        <p>Vaka-kontrol Ã§alÄ±ÅŸmalarÄ±, 1920'lerde Janet Lane-Claypon tarafÄ±ndan breast cancer araÅŸtÄ±rmasÄ±nda ilk kez sistematik olarak uygulanmÄ±ÅŸtÄ±r. Bu tasarÄ±m, nadir outcomes iÃ§in cost-effective epidemiological approach saÄŸlar.</p>

        <p><strong>Case Definition:</strong> Vaka tanÄ±mÄ±nÄ±n kesin ve objektif olmasÄ± kritiktir. Diagnostic criteria, standardize test results, clinical guidelines kullanÄ±lmalÄ±dÄ±r. Incident vs prevalent cases ayrÄ±mÄ± Ã¶nemlidir.</p>

        <h4>ğŸ‘¥ Kontrol SeÃ§im Stratejileri</h4>
        <p><strong>PopÃ¼lasyon Kontrolleri:</strong> AynÄ± source population'dan rastgele Ã¶rnekleme. Representative ancak katÄ±lÄ±m yanlÄ±lÄ±ÄŸÄ± riski yÃ¼ksek.</p>

        <p><strong>Hospital/Clinic Controls:</strong> AynÄ± healthcare facility'den. Participation rate yÃ¼ksek ancak seÃ§im yanlÄ±lÄ±ÄŸÄ± riski var.</p>

        <p><strong>Friend/Family Controls:</strong> Sosyodemografik benzerlik yÃ¼ksek. Overmatching riski var.</p>

        <p><strong>Matching Criteria:</strong> YaÅŸ, cinsiyet, sosyoekonomik statÃ¼ gibi Ã¶nemli confounders iÃ§in matching yapÄ±lÄ±r. 1:1, 1:2 veya 1:4 ratio'larÄ± kullanÄ±lÄ±r.</p>

        <h4>ğŸ“Š Odds Ratio HesaplamasÄ± ve Yorumu</h4>
        <p><strong>2x2 Contingency Table:</strong></p>
        <table style="border: 1px solid white; margin: 10px 0;">
            <tr><td></td><td>Case</td><td>Control</td></tr>
            <tr><td>Exposed</td><td>a</td><td>b</td></tr>
            <tr><td>Unexposed</td><td>c</td><td>d</td></tr>
        </table>
        <p><strong>Odds Ratio = (aÃ—d)/(bÃ—c)</strong></p>

        <p>OR = 1: No association, OR > 1: Positive association, OR < 1: Negative association</p>

        <h4>âš ï¸ Bias TÃ¼rleri ve KontrolÃ¼</h4>
        <p><strong>Recall Bias:</strong> Cases daha iyi hatÄ±rlar exposure'larÄ±. Objective measures (laboratory tests, medical records) kullanÄ±mÄ± Ã¶nerilir.</p>

        <p><strong>Selection Bias:</strong> Cases ve controls farklÄ± kaynaklardan seÃ§ilirse. Berkson's bias, hospital-based controls'da yaygÄ±n.</p>

        <p><strong>Information Bias:</strong> Exposure Ã¶lÃ§Ã¼mÃ¼ndeki sistematik hatalar. Blinded data collection ile minimize edilir.</p>

        <h4>ğŸƒâ€â™‚ï¸ Spor Yaralanma AraÅŸtÄ±rmalarÄ±nda Uygulama</h4>
        <p><strong>ACL Injury Risk Factors:</strong> ACL yaralanmasÄ± geÃ§iren atletler (cases) vs yaralanmasÄ± olmayan atletler (controls). Previous injury, biomechanical factors, hormonal status gibi risk faktÃ¶rleri analiz edilir.</p>

        <p><strong>Sudden Cardiac Death in Athletes:</strong> Nadir ama critical outcome. Autopsy findings, family history, pre-participation screening results karÅŸÄ±laÅŸtÄ±rÄ±lÄ±r.</p>
    </div>

    <div class="sidebar" id="sidebar-9">
        <h3>ğŸ“¸ Kesitsel Ã‡alÄ±ÅŸmalar: Snapshot Epidemiology</h3>
        <h4>ğŸ“Š Cross-Sectional Survey Methodology</h4>
        <p>Kesitsel Ã§alÄ±ÅŸmalar, tanÄ±mlayÄ±cÄ± epidemiyoloji'nin temelini oluÅŸturur. "Point-in-time" yaklaÅŸÄ±mÄ± ile population'daki exposure ve outcome prevalansÄ±nÄ± eÅŸ zamanlÄ± olarak Ã¶lÃ§er. HÄ±zlÄ±, relatively inexpensive ve hypothesis-generating Ã§alÄ±ÅŸmalar iÃ§in ideal.</p>

        <p><strong>Prevalence HesaplamasÄ±:</strong></p>
        <p>Prevalence = (Number of existing cases / Total population at risk) Ã— 100</p>
        <p>Point prevalence vs period prevalence ayrÄ±mÄ± Ã¶nemlidir.</p>

        <h4>ğŸ“‹ Survey Design Prensipleri</h4>
        <p><strong>Sampling Frame:</strong> Hedef popÃ¼lasyon'Ä±n complete listesi. Kapsam hatasÄ± minimize edilmeli.</p>

        <p><strong>Sample Size Calculation:</strong> Prevalence estimate iÃ§in:</p>
        <p>n = [ZÂ²Î±/2 Ã— P(1-P)] / dÂ²</p>
        <ul>
            <li>P = expected prevalence</li>
            <li>d = desired precision (margin of error)</li>
            <li>Z = Z-score for confidence level</li>
        </ul>

        <p><strong>Nonresponse Bias:</strong> Response rate <60% durumunda bias riski yÃ¼ksek. Weighting adjustments, multiple contact attempts gerekli.</p>

        <h4>ğŸ¯ Spor Bilimlerinde Kesitsel Ã‡alÄ±ÅŸma Ã–rnekleri</h4>
        <p><strong>Athlete Nutrition Surveys:</strong> NCAA athletes'larda supplement use prevalence, dietary pattern assessment. 24-hour dietary recall, food frequency questionnaires kullanÄ±lÄ±r.</p>

        <p><strong>Exercise Behavior Population Surveys:</strong> BRFSS (Behavioral Risk Factor Surveillance System) gibi national surveys. Physical activity guidelines adherence, sedentary behavior patterns analizi.</p>

        <p><strong>Body Composition Cross-Sectional Studies:</strong> Different sport disciplines'daki athletes'larÄ±n body fat percentage, muscle mass distributions. DEXA, BodPod, hydrostatic weighing methodlarÄ±.</p>

        <h4>âš ï¸ Causal Inference SÄ±nÄ±rlÄ±lÄ±klarÄ±</h4>
        <p><strong>Temporal Ambiguity:</strong> Exposure-outcome temporal sequence bilinemiyor. "Chicken or egg" problemi yaygÄ±n.</p>

        <p><strong>Survival Bias:</strong> Prevalent cases, incident cases'i represent etmeyebilir. Duration bias, length bias riskleri var.</p>

        <p><strong>Reverse Causation:</strong> Outcome, exposure'Ä± etkileyebilir. Exercise ve depression relationship'inde sÄ±k gÃ¶rÃ¼lÃ¼r.</p>
    </div>

    <div class="sidebar" id="sidebar-10">
        <h3>ğŸ“Š Meta-Analiz: KanÄ±t Sentezi</h3>
        <h4>ğŸ“š Meta-Analiz Metodolojisinin GeliÅŸimi</h4>
        <p>Meta-analiz terimi, Gene Glass tarafÄ±ndan 1976'da ortaya atÄ±lmÄ±ÅŸtÄ±r. "Analysis of analyses" olarak tanÄ±mlanÄ±r. Karl Pearson'un 1904'teki typhoid vaccine effectiveness Ã§alÄ±ÅŸmasÄ± ilk meta-analiz Ã¶rneÄŸi sayÄ±lÄ±r.</p>

        <p><strong>Cochrane Collaboration (1993):</strong> Sistematik derleme ve meta-analiz'in standardizasyonu. KanÄ±ta dayalÄ± tÄ±p'in temel taÅŸlarÄ±ndan biri.</p>

        <h4>ğŸ”¢ Effect Size HesaplamalarÄ±</h4>
        <p><strong>Standardized Mean Difference (Cohen's d):</strong></p>
        <p>d = (Mâ‚ - Mâ‚‚) / SDpooled</p>
        <p>Cohen's benchmarks: small (0.2), medium (0.5), large (0.8)</p>

        <p><strong>Hedges' g:</strong> YanlÄ±lÄ±ksÄ±z tahmin, kÃ¼Ã§Ã¼k Ã¶rneklem bÃ¼yÃ¼klÃ¼ÄŸÃ¼'lar iÃ§in preferred:</p>
        <p>g = d Ã— [1 - 3/(4(nâ‚ + nâ‚‚) - 9)]</p>

        <p><strong>Glass's Î”:</strong> Kontrol grubunun SD'si ile standardize edilir:</p>
        <p>Î” = (Mâ‚ - Mâ‚‚) / SD_control</p>

        <h4>ğŸ“Š Heterojenite DeÄŸerlendirmesi</h4>
        <p><strong>IÂ² Statistics:</strong> Heterogeneity'nin percentage'i:</p>
        <p>IÂ² = [(Q - df) / Q] Ã— 100%</p>
        <p>Interpretation: 0-40% (not important), 30-60% (moderate), 50-90% (substantial), 75-100% (considerable)</p>

        <p><strong>TauÂ² (Ï„Â²):</strong> Ã‡alÄ±ÅŸmalar arasÄ± varyans estimate. Rastgele etkiler modeli'in temeli.</p>

        <p><strong>Q-test:</strong> Cochrane's Q test, homojenlik sÄ±fÄ±r hipotezi'ini test eder.</p>

        <h4>ğŸ¯ Fixed vs Random Effects Models</h4>
        <p><strong>Fixed Effects (Mantel-Haenszel):</strong> True effect size tÃ¼m Ã§alÄ±ÅŸmalarda aynÄ± varsayÄ±mÄ±. Precision-weighted average.</p>

        <p><strong>Random Effects (DerSimonian-Laird):</strong> GerÃ§ek etki bÃ¼yÃ¼klÃ¼kleri normal daÄŸÄ±lÄ±m gÃ¶sterir. Ã‡alÄ±ÅŸmalar arasÄ± varyans hesaba katÄ±lÄ±r.</p>

        <h4>ğŸ“ˆ Publication Bias Testi</h4>
        <p><strong>Funnel Plot:</strong> Effect size vs standard error grafiÄŸi. Asymmetry bias gÃ¶sterir.</p>

        <p><strong>Egger's Test:</strong> Huni grafiÄŸi asimetrisi'sinin istatistiksel test.</p>

        <p><strong>Trim and Fill Method:</strong> Missing studies'i estimate eder.</p>

        <h4>ğŸ‹ï¸â€â™€ï¸ Spor Bilimlerinde Meta-Analiz Ã–rnekleri</h4>
        <p><strong>Protein Supplementation Meta-Analyses:</strong> Resistance training ile birlikte protein takviyesinin muscle mass ve strength Ã¼zerindeki etkisi. Dose-response relationships analizi.</p>

        <p><strong>HIIT vs MICT Meta-Analyses:</strong> High-intensity interval training'in moderate-intensity continuous training ile karÅŸÄ±laÅŸtÄ±rmasÄ±. Cardiovascular adaptations, body composition changes.</p>
    </div>

    <div class="sidebar" id="sidebar-11">
        <h3>ğŸ”€ Karma YÃ¶ntem: Methodological Triangulation</h3>
        <h4>ğŸ­ Mixed Methods Paradigma</h4>
        <p>Karma yÃ¶ntem araÅŸtÄ±rmalar, John Creswell ve Vicki Plano Clark'Ä±n Ã¶ncÃ¼lÃ¼ÄŸÃ¼nde 1990'larda systematize edilmiÅŸtir. "ÃœÃ§Ã¼ncÃ¼ araÅŸtÄ±rma paradigmasÄ±" olarak tanÄ±mlanÄ±r, nicel ve nitel yaklaÅŸÄ±mlar'larÄ±n integration'Ä± ile kapsamlÄ± anlayÄ±ÅŸ saÄŸlar.</p>

        <p><strong>Pragmatist DÃ¼nya GÃ¶rÃ¼ÅŸÃ¼:</strong> John Dewey'in pragmatist felsefesi temelinde, "what works" yaklaÅŸÄ±mÄ±. YÃ¶ntem seÃ§imi, research question'a gÃ¶re yapÄ±lÄ±r.</p>

        <h4>ğŸ”„ Core Mixed Methods Designs</h4>
        <p><strong>Explanatory Sequential (QUAN â†’ qual):</strong></p>
        <ul>
            <li>Phase 1: Quantitative data collection ve analysis</li>
            <li>Phase 2: Qualitative follow-up nicel results'larÄ± aÃ§Ä±klar</li>
            <li>Integration: Interpretation aÅŸamasÄ±nda</li>
            <li>Purpose: Quantitative findings'lerin deeper understanding</li>
        </ul>

        <p><strong>Exploratory Sequential (QUAL â†’ quan):</strong></p>
        <ul>
            <li>Phase 1: Qualitative exploration</li>
            <li>Phase 2: Quantitative testing of qualitative themes</li>
            <li>Integration: Building from qual to quan</li>
            <li>Purpose: Instrument development, hypothesis generation</li>
        </ul>

        <p><strong>Concurrent Triangulation (QUAN + QUAL):</strong></p>
        <ul>
            <li>Simultaneous data collection</li>
            <li>Equal weight to both approaches</li>
            <li>Integration: Results comparison ve corroboration</li>
            <li>Purpose: Validation, complementarity</li>
        </ul>

        <h4>ğŸ¯ Integration Strategies</h4>
        <p><strong>Data Integration:</strong> Joint displays, side-by-side comparison, data transformation (qualitizing, quantitizing).</p>

        <p><strong>Methods Integration:</strong> Concurrent data collection, sama participants, integrated sampling strategy.</p>

        <p><strong>Interpretation Integration:</strong> Discussion'da both datasets'in findings'lerinin synthesis.</p>

        <h4>ğŸƒâ€â™‚ï¸ Spor Bilimlerinde Mixed Methods</h4>
        <p><strong>Performance Enhancement Research:</strong> Physiological measurements (VOâ‚‚max, lactate threshold) + athlete experiences (perceived exertion, motivation, training satisfaction). Complete picture of training effectiveness.</p>

        <p><strong>Injury Prevention Studies:</strong> Biomechanical analysis (motion capture, force platforms) + athlete interviews (risk perception, compliance barriers). Multi-factorial injury etiology understanding.</p>

        <p><strong>Team Dynamics Research:</strong> Performance metrics (win/loss, statistics) + team climate surveys + coach/player interviews. Holistic team functioning assessment.</p>

        <h4>ğŸ” Quality Criteria</h4>
        <p><strong>Legitimation:</strong> Mixed methods research'in validity/credibility criteria. Onwuegbuzie ve Johnson'Ä±n framework: sample integration legitimation, weakness minimization legitimation, sequential legitimation.</p>
    </div>

    <div class="sidebar" id="sidebar-12">
        <h3>ğŸ¯ Ä°Ã§ GeÃ§erlik: Internal Validity Threats</h3>
        <h4>ğŸ›ï¸ Campbell'Ä±n Ä°Ã§ GeÃ§erlik SÄ±nÄ±flandÄ±rmasÄ±</h4>
        <p>Donald Campbell ve Julian Stanley (1963) tarafÄ±ndan sistematize edilen iÃ§ geÃ§erlik tehditleri, causal inference'Ä±n validity'sini tehdit eden faktÃ¶rlerdir. Shadish, Cook ve Campbell (2002) bu listeyi gÃ¼ncelleyerek expanded taxonomy oluÅŸturmuÅŸtur.</p>

        <h4>ğŸ“… History Threats</h4>
        <p><strong>Specific Historical Events:</strong> Treatment ile outcome measurement arasÄ±nda gerÃ§ekleÅŸen external events. Spor araÅŸtÄ±rmalarÄ±nda Ã¶rnek: antrenman periyodu sÄ±rasÄ±nda major competition, injury outbreak, weather changes.</p>

        <p><strong>Local History:</strong> Sadece treatment group'u etkileyen events. Experimental group'un farklÄ± facilities kullanmasÄ± durumunda yaygÄ±n.</p>

        <p><strong>KontrolÃ¼:</strong> Randomization, control group usage, multiple site studies ile minimize edilir.</p>

        <h4>ğŸŒ± Maturation Effects</h4>
        <p><strong>Natural Development:</strong> Participants'larÄ±n time passage ile natural changes'larÄ±. Children sports studies'da kritik concern.</p>

        <p><strong>Training Adaptations:</strong> Spor bilimlerinde Ã¶zel maturation type. Ongoing training effects, seasonal adaptations.</p>

        <p><strong>Fatigue/Recovery Cycles:</strong> Measurement timing'ine baÄŸlÄ± fluctuations. Circadian rhythm, weekly training cycles effects.</p>

        <h4>ğŸ“ Testing Effects</h4>
        <p><strong>Pre-test Sensitization:</strong> Pre-test exposure'Ä±n post-test performance'Ä±nÄ± etkilemesi. Motor learning, practice effects yaygÄ±n.</p>

        <p><strong>Reactive Testing:</strong> Test administration'Ä±n treatment effectiveness'ini modify etmesi. Placebo effect, Hawthorne effect ile iliÅŸkili.</p>

        <p><strong>Testing Fatigue:</strong> Repeated testing'den kaynaklanan performance decrement. Cognitive tests, physical performance measures'da gÃ¶rÃ¼lÃ¼r.</p>

        <h4>ğŸ“Š Statistical Regression</h4>
        <p><strong>Regression to the Mean:</strong> Extreme scores'larÄ±n subsequent measurements'ta ortalamaya yaklaÅŸma tendency'si. Selection based on extreme performance'da yaygÄ±n.</p>

        <p><strong>Mathematical Phenomenon:</strong> Measurement error'dan kaynaklanan statistical artifact. True score + error component'in doÄŸasÄ±.</p>

        <p><strong>Prevention:</strong> Random assignment, multiple pre-tests, reliable measurement instruments kullanÄ±mÄ±.</p>

        <h4>ğŸ‘¥ Selection Bias</h4>
        <p><strong>Differential Group Characteristics:</strong> Non-randomized group assignment'ta systematic group differences. Intact groups usage'da yaygÄ±n.</p>

        <p><strong>Self-Selection:</strong> Participants'larÄ±n treatment groups'Ä± seÃ§mesi. Volunteer bias, motivation differences yaratÄ±r.</p>

        <p><strong>Baseline Imbalances:</strong> Randomization failure veya chance imbalances. Prognostic factors'da group differences.</p>
    </div>

    <div class="sidebar" id="sidebar-13">
        <h3>ğŸŒ DÄ±ÅŸ GeÃ§erlik: Genellenebilirlik</h3>
        <h4>ğŸ¯ External Validity Dimensions</h4>
        <p>DÄ±ÅŸ geÃ§erlik, research findings'lerin baÅŸka populations, settings, treatments ve outcomes'lara generalizability'sini ifade eder. Lee Cronbach'Ä±n UTOS framework'Ã¼ (Units, Treatments, Outcomes, Settings) dÄ±ÅŸ geÃ§erlik boyutlarÄ±nÄ± systematize eder.</p>

        <h4>ğŸ‘¥ Population Validity</h4>
        <p><strong>Target Population Definition:</strong> Research findings'lerin generalize edileceÄŸi population'Ä±n net tanÄ±mÄ±. Age, gender, skill level, health status gibi characteristics.</p>

        <p><strong>Accessible Population:</strong> Researcher'Ä±n actually reach edebildiÄŸi population. Geographic, institutional constraints ile sÄ±nÄ±rlÄ±.</p>

        <p><strong>Sample Representativeness:</strong> Sampling method ve response rate'in representativeness Ã¼zerindeki etkisi. Volunteer bias, seÃ§im yanlÄ±lÄ±ÄŸÄ± riskleri.</p>

        <p><strong>Elite vs Recreational Athletes:</strong> Elite athlete findings'lerin recreational exercisers'a generalizability'si questionable. Different physiological capacity, training background, motivation levels.</p>

        <h4>ğŸ›ï¸ Ecological Validity</h4>
        <p><strong>Laboratory vs Field Settings:</strong> Controlled lab conditions'larÄ±n real-world applicability'si. Artificial environment effects on behavior ve performance.</p>

        <p><strong>Equipment/Technology Effects:</strong> Research-grade equipment vs commercially available alternatives. Cost-benefit considerations for practical implementation.</p>

        <p><strong>Social Environment:</strong> Individual testing vs team/group settings. Peer influence, competition effects on performance outcomes.</p>

        <h4>â° Temporal Validity</h4>
        <p><strong>Historical Context:</strong> Research findings'lerin different time periods'daki relevance. Technology advancement, cultural changes effects.</p>

        <p><strong>Seasonal Effects:</strong> Training periodization, competitive season impacts. Off-season vs in-season generalizability issues.</p>

        <p><strong>Long-term vs Short-term Effects:</strong> Acute findings'lerin chronic implications'a extrapolation validity. Adaptation plateau, sustainability questions.</p>

        <h4>ğŸ’Š Treatment Validity</h4>
        <p><strong>Intervention Fidelity:</strong> Standardized treatment delivery vs real-world implementation variability. Dosage, frequency, duration modifications.</p>

        <p><strong>Adherence Differences:</strong> Research setting'deki high compliance vs practical setting'deki variable adherence. Intention-to-treat vs per-protocol analysis implications.</p>

        <p><strong>Contextual Factors:</strong> Supportive research environment vs independent practice. Motivation, supervision, feedback differences.</p>

        <h4>ğŸ”„ Trade-offs ile Ä°Ã§ GeÃ§erlik</h4>
        <p>Internal validity artÄ±rmak iÃ§in yapÄ±lan controls, external validity'yi sÄ±nÄ±rlayabilir. Randomization, blinding, standardization gibi procedures real-world applicability'yi azaltÄ±r. Pragmatic trials bu balance'Ä± optimize etmeye Ã§alÄ±ÅŸÄ±r.</p>
    </div>

    <div class="sidebar" id="sidebar-14">
        <h3>ğŸ—ï¸ YapÄ± GeÃ§erliÄŸi: Construct Validity</h3>
        <h4>ğŸ“Š Cronbach & Meehl'in Temel KatkÄ±sÄ±</h4>
        <p>Lee Cronbach ve Paul Meehl (1955), "Construct validity in psychological tests" Ã§alÄ±ÅŸmasÄ±nda construct validity kavramÄ±nÄ± sistematize etmiÅŸtir. Nomological network teorisi ile constructs'larÄ±n theoretical framework iÃ§indeki relationships'ini tanÄ±mlamÄ±ÅŸlardÄ±r.</p>

        <p><strong>Nomological Network:</strong> Theoretical constructs arasÄ±ndaki expected relationships'in network'Ã¼. Observable variables ile latent constructs arasÄ±ndaki connections.</p>

        <h4>ğŸ”„ Campbell & Fiske'nin MTMM Matrix</h4>
        <p><strong>Multitrait-Multimethod Matrix (1959):</strong> Convergent ve discriminant validity'nin sistematik assessment'i iÃ§in develop edilmiÅŸtir.</p>

        <p><strong>Convergent Validity:</strong> Same construct'Ä± measure eden different methods arasÄ±nda high correlation expected. Monomethod bias'Ä± eliminate eder.</p>

        <p><strong>Discriminant Validity:</strong> Different constructs arasÄ±nda low correlation expected, same method kullanÄ±lsa bile. Method variance vs trait variance separation.</p>

        <h4>ğŸ“ Validity Evidence KaynaklarÄ±</h4>
        <p><strong>Content Validity:</strong> Test content'inin construct domain'Ä±nÄ± adequately represent etmesi. Expert judgment, content analysis methods ile assess edilir.</p>

        <p><strong>Criterion Validity:</strong></p>
        <ul>
            <li><strong>Concurrent:</strong> External criterion ile simultaneous correlation</li>
            <li><strong>Predictive:</strong> Future criterion performance'Ä±n prediction accuracy'si</li>
        </ul>

        <p><strong>Face Validity:</strong> Test'in subjective appropriateness appearance. Validity evidence olarak insufficient ancak acceptance iÃ§in important.</p>

        <h4>ğŸ” Factor Analysis in Validity</h4>
        <p><strong>Exploratory Factor Analysis (EFA):</strong> Underlying factor structure'Ä±n discovery'si iÃ§in. Principal axis factoring, maximum likelihood extraction methods.</p>

        <p><strong>Confirmatory Factor Analysis (CFA):</strong> Hypothesized factor model'in test edilmesi. Structural equation modeling framework iÃ§inde.</p>

        <p><strong>Model Fit Indices:</strong></p>
        <ul>
            <li>CFI (Comparative Fit Index) > 0.95</li>
            <li>RMSEA (Root Mean Square Error of Approximation) < 0.06</li>
            <li>SRMR (Standardized Root Mean Square Residual) < 0.08</li>
        </ul>

        <h4>ğŸƒâ€â™‚ï¸ Spor Bilimlerinde Construct Validity</h4>
        <p><strong>Performance Measurement:</strong> Athletic performance construct'Ä±nÄ±n operationalization'Ä± complex. Multiple dimensions: technical skill, physical capacity, tactical knowledge, psychological factors.</p>

        <p><strong>Motivation Constructs:</strong> Intrinsic vs extrinsic motivation measurement. Self-Determination Theory framework'Ã¼nde autonomy, competence, relatedness constructs'larÄ±nÄ±n validity evidence.</p>

        <p><strong>Physical Fitness Components:</strong> Cardiovascular endurance, muscular strength, flexibility, body composition constructs'larÄ±nÄ±n discriminant validity. Component-specific vs general fitness factor debate.</p>
    </div>

    <div class="sidebar" id="sidebar-15">
        <h3>ğŸ“ˆ Ä°statistiksel SonuÃ§ GeÃ§erliÄŸi</h3>
        <h4>ğŸ¯ Statistical Conclusion Validity Framework</h4>
        <p>Cook ve Campbell (1979) tarafÄ±ndan tanÄ±mlanan statistical conclusion validity, statistical inference'larÄ±n appropriateness ve accuracy'sini deÄŸerlendiren validity type'Ä±dÄ±r. Type I ve Type II error control'Ã¼, effect size estimation, istatistiksel gÃ¼Ã§ analysis'i kapsar.</p>

        <h4>ğŸ”¬ Type I Error (Alpha Level)</h4>
        <p><strong>False Positive Rate:</strong> Null hypothesis doÄŸru olmasÄ±na raÄŸmen reject etme probability'si. Conventionally Î± = 0.05 level set edilir.</p>

        <p><strong>Family-wise Error Rate (FWER):</strong> Multiple comparisons'da Type I error inflation. Bonferroni correction: Î±adjusted = Î±/k (k = number of tests).</p>

        <p><strong>False Discovery Rate (FDR):</strong> Benjamini-Hochberg procedure ile control. Large-scale hypothesis testing'de preferred.</p>

        <h4>ğŸ’ª Statistical Power Analysis</h4>
        <p><strong>Power Components:</strong></p>
        <ul>
            <li>Effect size (Cohen's conventions)</li>
            <li>Sample size (n per group)</li>
            <li>Alpha level (Type I error rate)</li>
            <li>Power (1 - Î², Type II error rate)</li>
        </ul>

        <p><strong>Cohen's Effect Size Benchmarks:</strong></p>
        <ul>
            <li>Small effect: d = 0.2, r = 0.1, Î·Â² = 0.01</li>
            <li>Medium effect: d = 0.5, r = 0.3, Î·Â² = 0.06</li>
            <li>Large effect: d = 0.8, r = 0.5, Î·Â² = 0.14</li>
        </ul>

        <p><strong>A Priori Power Analysis:</strong> Sample size determination iÃ§in. G*Power software widely used. Minimum detectable effect size calculation.</p>

        <h4>ğŸ“Š Effect Size Reporting</h4>
        <p><strong>Standardized Effect Sizes:</strong> Cohen's d, Hedges' g, Glass's Î” for mean differences. Eta-squared, omega-squared for ANOVA.</p>

        <p><strong>Confidence Intervals:</strong> Effect size'Ä±n precision indication. CI width, Ã¶rneklem bÃ¼yÃ¼klÃ¼ÄŸÃ¼ ile inversely related.</p>

        <p><strong>Clinical vs Statistical Significance:</strong> Statistically significant findings'in practical importance assessment. Minimal clinically important difference (MCID) concept.</p>

        <h4>âš ï¸ Statistical Assumptions</h4>
        <p><strong>Parametric Test Assumptions:</strong></p>
        <ul>
            <li>Normality: Shapiro-Wilk test, Q-Q plots</li>
            <li>Homogeneity of variance: Levene's test, Brown-Forsythe test</li>
            <li>Independence: Study design issue, not statistically testable</li>
        </ul>

        <p><strong>Violation Consequences:</strong> Type I error inflation, power reduction, biased effect size estimates. Robust statistical methods alternative.</p>

        <h4>ğŸ‹ï¸â€â™€ï¸ Spor Bilimlerinde Ã–zel Durumlar</h4>
        <p><strong>Repeated Measures:</strong> Within-subject correlation violation of independence. Mixed-effects modeling, GEE approaches recommended.</p>

        <p><strong>Non-normal Distributions:</strong> Performance data'da ceiling/floor effects. Transformation, non-parametric alternatives consideration.</p>
    </div>

    <div class="sidebar" id="sidebar-16">
        <h3>ğŸ¯ GÃ¼venirlik: Measurement Consistency</h3>
        <h4>ğŸ“Š Classical Test Theory</h4>
        <p>Reliability, Classical Test Theory (CTT) framework'Ã¼nde observed score'un consistency'sini ifade eder. Spearman (1904) ve Brown (1910) tarafÄ±ndan theoretical foundation'Ä± atÄ±lmÄ±ÅŸtÄ±r.</p>

        <p><strong>True Score Model:</strong> X = T + E</p>
        <ul>
            <li>X = Observed score</li>
            <li>T = True score</li>
            <li>E = Error score</li>
        </ul>

        <p><strong>Reliability Coefficient:</strong> r = ÏƒÂ²T / ÏƒÂ²X = ÏƒÂ²T / (ÏƒÂ²T + ÏƒÂ²E)</p>
        <p>True score variance'Ä±n total variance'a oranÄ±.</p>

        <h4>ğŸ”„ Reliability Types</h4>
        <p><strong>Test-Retest Reliability:</strong> Temporal stability, same instrument ile repeated measurement correlation. Time interval kritik: too short (memory effects), too long (trait changes).</p>

        <p><strong>Parallel Forms Reliability:</strong> Equivalent test versions'larÄ±n consistency'si. Item sampling'den kaynaklanan error variance estimation.</p>

        <p><strong>Internal Consistency:</strong></p>
        <ul>
            <li>Cronbach's Alpha (Î±): Average inter-item correlation based</li>
            <li>Split-half reliability: Two halves correlation, Spearman-Brown correction</li>
            <li>McDonald's Omega (Ï‰): Factor analysis based, more robust</li>
        </ul>

        <h4>ğŸ‘¥ Inter-rater ve Intra-rater Reliability</h4>
        <p><strong>Inter-rater Reliability:</strong> Different raters arasÄ±ndaki agreement. Cohen's kappa (categorical), ICC (continuous data).</p>

        <p><strong>Intra-rater Reliability:</strong> Same rater'Ä±n different occasions'daki consistency'si. Within-rater variability assessment.</p>

        <p><strong>Intraclass Correlation Coefficient (ICC):</strong></p>
        <ul>
            <li>ICC(1,1): Single measurement, random raters</li>
            <li>ICC(2,1): Single measurement, fixed raters</li>
            <li>ICC(3,1): Single measurement, absolute agreement</li>
        </ul>

        <h4>ğŸ“ Standard Error of Measurement</h4>
        <p><strong>SEM Calculation:</strong> SEM = SD Ã— âˆš(1-r)</p>
        <p>Individual score'un precision indication. Confidence interval construction iÃ§in kullanÄ±lÄ±r.</p>

        <p><strong>Minimal Detectable Change (MDC):</strong> MDC = SEM Ã— 1.96 Ã— âˆš2</p>
        <p>95% confidence level'da true change detection threshold.</p>

        <h4>ğŸƒâ€â™‚ï¸ Spor Bilimlerinde Reliability Challenges</h4>
        <p><strong>Performance Variability:</strong> Athletic performance'da natural fluctuation high. Biological variation vs measurement error separation difficult.</p>

        <p><strong>Learning Effects:</strong> Motor skill assessments'da practice effects. Familiarization sessions necessity.</p>

        <p><strong>Motivation/Effort Variability:</strong> Maximal effort tests'da internal motivation differences. Standardized encouragement protocols.</p>

        <p><strong>Environmental Factors:</strong> Temperature, humidity, wind conditions effect on outdoor performance tests. Standardization vs ecological validity trade-off.</p>
    </div>

    <div class="sidebar" id="sidebar-17">
        <h3>ğŸ“Š Ã–rneklem BÃ¼yÃ¼klÃ¼ÄŸÃ¼ ve GÃ¼Ã§ Analizi</h3>
        <h4>ğŸ¯ Power Analysis Theory</h4>
        <p>Statistical power, Jacob Cohen (1988) tarafÄ±ndan "Statistical Power Analysis for the Behavioral Sciences" kitabÄ±nda systematize edilmiÅŸtir. Power analysis, Type II error (Î²) control ve adequate Ã¶rneklem bÃ¼yÃ¼klÃ¼ÄŸÃ¼ determination iÃ§in essential tool.</p>

        <p><strong>Power Components Relationship:</strong></p>
        <ul>
            <li>â†‘ Effect size â†’ â†‘ Power</li>
            <li>â†‘ Sample size â†’ â†‘ Power</li>
            <li>â†‘ Alpha level â†’ â†‘ Power (â†‘ Type I error risk)</li>
            <li>â†“ Population variability â†’ â†‘ Power</li>
        </ul>

        <h4>ğŸ“ˆ A Priori vs Post-hoc Analysis</h4>
        <p><strong>A Priori Power Analysis:</strong> Study design stage'de Ã¶rneklem bÃ¼yÃ¼klÃ¼ÄŸÃ¼ determination. Required inputs: expected effect size, desired power (typically 0.80), alpha level (typically 0.05).</p>

        <p><strong>Post-hoc Power Analysis:</strong> Controversial practice. "Power of the test you did" calculation. Observed power always low when p > 0.05. Alternative: confidence intervals, effect size reporting.</p>

        <p><strong>Sensitivity Analysis:</strong> Minimum detectable effect size calculation given fixed Ã¶rneklem bÃ¼yÃ¼klÃ¼ÄŸÃ¼. Study limitations assessment iÃ§in useful.</p>

        <h4>ğŸ“Š Effect Size Estimation Strategies</h4>
        <p><strong>Literature-Based Estimates:</strong> Previous similar studies'dan effect size extraction. Meta-analysis results ideal source.</p>

        <p><strong>Pilot Study Estimates:</strong> Small-scale preliminary study. Unstable estimates risk, large confidence intervals.</p>

        <p><strong>Clinical/Practical Significance:</strong> Meaningful change threshold'larÄ±. MCID (Minimal Clinically Important Difference) concept.</p>

        <p><strong>Cohen's Conventions:</strong> Last resort when no better information available. Field-specific benchmarks more appropriate when available.</p>

        <h4>âš™ï¸ Software Tools</h4>
        <p><strong>G*Power:</strong> Free, comprehensive power analysis software. User-friendly interface, wide test coverage.</p>

        <p><strong>R Packages:</strong> pwr, WebPower, simr packages. Flexible programming environment, complex designs support.</p>

        <p><strong>Commercial Software:</strong> PASS, nQuery, SAS/PROC POWER. Advanced features, regulatory compliance.</p>

        <h4>ğŸ“Š Complex Design Considerations</h4>
        <p><strong>Repeated Measures:</strong> Within-subject correlation effect on power. Compound symmetry assumption, unstructured covariance modeling.</p>

        <p><strong>Cluster Randomized Trials:</strong> Intracluster correlation (ICC) coefficient effect. Design effect = 1 + (m-1) Ã— ICC, where m = cluster size.</p>

        <p><strong>Factorial Designs:</strong> Main effects vs interaction power. Interaction detection requires larger Ã¶rneklem bÃ¼yÃ¼klÃ¼ÄŸÃ¼s.</p>

        <h4>ğŸƒâ€â™‚ï¸ Spor Bilimlerinde Ã–zel Durumlar</h4>
        <p><strong>Attrition/Dropout:</strong> Longitudinal sports studies'da high dropout rates. Inflation factors: 20-30% additional participants recruitment.</p>

        <p><strong>Seasonal Effects:</strong> Training periodization'Ä±n effect size'a etkisi. Pre-season vs in-season power differences.</p>

        <p><strong>Individual Response Variability:</strong> High inter-individual differences sports performance'da. Precision medicine approaches, responder analysis.</p>
    </div>

    <div class="sidebar" id="sidebar-18">
        <h3>ğŸ² Randomizasyon: Bias Elimination</h3>
        <h4>ğŸ›ï¸ Fisher'Ä±n Randomization Ä°lkesi</h4>
        <p>Ronald Fisher (1925), "Statistical Methods for Research Workers" ve "The Design of Experiments" (1935) Ã§alÄ±ÅŸmalarÄ±nda randomization'Ä±n theoretical foundation'Ä±nÄ± atmÄ±ÅŸtÄ±r. Randomization, known ve unknown karÄ±ÅŸtÄ±rÄ±cÄ± deÄŸiÅŸkens'larÄ± groups arasÄ±nda balance eder.</p>

        <p><strong>Randomization Distribution Theory:</strong> Treatment assignment'Ä±n probability distribution'Ä±. Permutation-based inference'Ä±n temeli. Fisher's exact test, randomization test methodology.</p>

        <h4>ğŸ¯ Simple Randomization</h4>
        <p><strong>Random Number Generation:</strong> Pseudo-random number generators (PRNG) vs true random number generators. Computer-based allocation sequences.</p>

        <p><strong>Coin Tossing:</strong> Classical simple randomization method. Equal probability (p = 0.5) assumption. Large samples'da balance guarantee.</p>

        <p><strong>Random Number Tables:</strong> Pre-generated random sequences. Historical method, computer algorithms replacement.</p>

        <h4>ğŸ§± Block Randomization</h4>
        <p><strong>Fixed Block Size:</strong> Predetermined block length (usually multiples of number of treatments). Perfect balance within each block guaranteed.</p>

        <p><strong>Variable Block Size:</strong> Random selection among different block sizes. Allocation prediction'Ä± zorlaÅŸtÄ±rÄ±r, allocation concealment artÄ±rÄ±r.</p>

        <p><strong>Permuted Block Design:</strong> Within-block permutations of treatment sequences. Balanced allocation maintenance.</p>

        <h4>ğŸ“Š Stratified Randomization</h4>
        <p><strong>Prognostic Factor Stratification:</strong> Important baseline characteristics'e gÃ¶re separate randomization lists. Age groups, gender, baseline performance levels.</p>

        <p><strong>Stratification Variables Selection:</strong> Strong prognostic factors priority. Too many strata â†’ small subgroup sizes. Maximum 3-4 stratification factors recommended.</p>

        <h4>âš–ï¸ Minimization (Dynamic Allocation)</h4>
        <p><strong>Pocock & Simon Method (1975):</strong> Real-time balance optimization algorithm. Each new participant allocation, current imbalance'Ä± minimize eder.</p>

        <p><strong>Imbalance Score Calculation:</strong> Weighted sum of imbalances across stratification factors. Biased coin assignment based on imbalance score.</p>

        <p><strong>Deterministic vs Probabilistic:</strong> Pure minimization (deterministic) vs biased coin minimization (probabilistic). Predictability vs balance trade-off.</p>

        <h4>ğŸ¥ Cluster Randomization</h4>
        <p><strong>Group-level Assignment:</strong> Intact clusters (teams, schools, clinics) randomization. Individual randomization impractical/unethical situations iÃ§in.</p>

        <p><strong>Intracluster Correlation (ICC):</strong> Within-cluster similarity effect. Sample size calculation'da design effect consideration.</p>

        <p><strong>Cluster Size Variation:</strong> Unequal cluster sizes'Ä±n analysis Ã¼zerindeki etkisi. Weighted vs unweighted analysis approaches.</p>

        <h4>ğŸ”’ Allocation Concealment</h4>
        <p><strong>Selection Bias Prevention:</strong> Next allocation prediction'Ä±nÄ±n prevention'Ä±. Investigator bias, participant seÃ§im yanlÄ±lÄ±ÄŸÄ± elimination.</p>

        <p><strong>SNOSE Method:</strong> Sequentially Numbered Opaque Sealed Envelopes. Low-tech, effective concealment method.</p>

        <p><strong>Central Randomization:</strong> Remote allocation via phone, web-based systems. Real-time allocation, automatic concealment.</p>
    </div>

    <div class="sidebar" id="sidebar-19">
        <h3>ğŸ‘ï¸ KÃ¶rleme: Performance Bias Control</h3>
        <h4>ğŸ­ Blinding Methodology</h4>
        <p>KÃ¶rleme (blinding/masking), performance bias ve detection bias'Ä± minimize etmek iÃ§in developed methodology. Participant expectations, investigator bias, outcome assessor preconceptions'Ä±n elimination'Ä± iÃ§in critical.</p>

        <p><strong>Historical Development:</strong> Ä°lk controlled trial (1747, James Lind scurvy study) kÃ¶rleme iÃ§ermiyordu. Modern blinding concept, 20. yÃ¼zyÄ±lda pharmaceutical research ile geliÅŸti.</p>

        <h4>ğŸ‘¤ Single Blinding</h4>
        <p><strong>Participant Blinding:</strong> Treatment assignment information'Ä± participants'tan hidden. Placebo effect, expectancy bias reduction.</p>

        <p><strong>Assessor Blinding:</strong> Outcome measurement yapan personel treatment assignment'Ä± bilmiyor. Detection bias prevention, objective measurement.</p>

        <p><strong>Investigator Blinding:</strong> Principal investigators treatment allocation'Ä± bilmiyor. Conduct bias, differential treatment delivery prevention.</p>

        <h4>ğŸ‘¥ Double Blinding</h4>
        <p><strong>Participant + Investigator:</strong> En yaygÄ±n double-blind configuration. Both treatment delivery ve participation expectation control.</p>

        <p><strong>Participant + Assessor:</strong> Investigator bilir (treatment delivery iÃ§in), assessor bilmez. Outcome measurement objectivity preservation.</p>

        <h4>ğŸ¯ Triple Blinding</h4>
        <p><strong>Complete Blinding:</strong> Participants, investigators, ve data analysts treatment assignment bilmiyor. Statistical analysis bias elimination.</p>

        <p><strong>Data Safety Monitoring Board (DSMB):</strong> Independent committee, unblinded interim analysis iÃ§in. Safety monitoring, efficacy assessment authorization.</p>

        <h4>ğŸ’Š Placebo Development</h4>
        <p><strong>Indistinguishable Placebo:</strong> Active treatment ile identical appearance, taste, smell. Matching physical properties kritik.</p>

        <p><strong>Active Placebo:</strong> Minor side effects Ã¼reten placebo. True blinding maintenance, side effect-based unblinding prevention.</p>

        <h4>ğŸ‹ï¸â€â™€ï¸ Spor Bilimlerinde KÃ¶rleme Challenges</h4>
        <p><strong>Exercise Interventions:</strong> Physical activity type'Ä± hide etmek impossible. Attention control groups, sham exercises alternative.</p>

        <p><strong>Nutrition Supplements:</strong> Taste, texture differences blinding compromise edebilir. Flavoring, capsule encapsulation solutions.</p>

        <p><strong>Equipment-based Interventions:</strong> Different training devices blinding zor. Similar-appearing equipment development, standardized protocols.</p>

        <h4>ğŸ” Blinding Assessment</h4>
        <p><strong>Blinding Success Evaluation:</strong> Post-study questionnaire, treatment guess accuracy assessment. Bang's blinding index calculation.</p>

        <p><strong>Blinding Index Formula:</strong> BI = (proportion correctly guessed - 0.5) / 0.5</p>
        <p>Values: -1 (opposite guessing) to +1 (perfect guessing), 0 = random guessing.</p>

        <h4>ğŸ“Š Analysis Implications</h4>
        <p><strong>Unblinding Effects:</strong> Differential unblinding groups arasÄ±nda bias introduce edebilir. Per-protocol vs intention-to-treat analysis consideration.</p>

        <p><strong>Sensitivity Analysis:</strong> Blinding failure scenarios'nÄ±n results Ã¼zerindeki potential impact assessment.</p>
    </div>

    <div class="sidebar" id="sidebar-20">
        <h3>âš–ï¸ AraÅŸtÄ±rma EtiÄŸi: Ä°nsan HaklarÄ± KorunmasÄ±</h3>
        <h4>ğŸ“œ Belmont Report'un Ã–nemi</h4>
        <p>1979 Belmont Report, National Commission for the Protection of Human Subjects'Ä±n Ã§alÄ±ÅŸmasÄ±dÄ±r. Tuskegee Syphilis Study scandal'Ä± sonrasÄ± biomedical research ethics'in modernization'Ä± iÃ§in critical document.</p>

        <p><strong>ÃœÃ§ Temel Ä°lke:</strong></p>
        <ul>
            <li><strong>Respect for Persons:</strong> Individual autonomy recognition + protection of diminished autonomy</li>
            <li><strong>Beneficence:</strong> Do no harm + maximize benefits, minimize harms</li>
            <li><strong>Justice:</strong> Fair distribution of research benefits ve burdens</li>
        </ul>

        <h4>ğŸ“‹ Informed Consent Process</h4>
        <p><strong>Information Component:</strong></p>
        <ul>
            <li>Research purpose ve procedures</li>
            <li>Risks ve discomforts</li>
            <li>Benefits (individual ve societal)</li>
            <li>Alternative procedures</li>
            <li>Confidentiality measures</li>
            <li>Compensation/medical treatment</li>
            <li>Contact information</li>
            <li>Voluntary participation</li>
        </ul>

        <p><strong>Comprehension Assessment:</strong> Understanding verification through teach-back method, comprehension quizzes. Health literacy, language barriers consideration.</p>

        <p><strong>Voluntariness Assurance:</strong> Coercion absence, undue influence elimination. Power dynamics awareness (employer-employee, teacher-student).</p>

        <h4>ğŸ‘¶ Vulnerable Populations</h4>
        <p><strong>Children (Minors):</strong> Parental permission + child assent (â‰¥7 years). Developmental capacity assessment, age-appropriate explanations.</p>

        <p><strong>Cognitively Impaired:</strong> Capacity assessment, surrogate decision-makers. Fluctuating capacity consideration, best interest standard.</p>

        <p><strong>Prisoners:</strong> Coercion vulnerability, minimal risk research limitation. Independent advocate necessity, post-release follow-up issues.</p>

        <p><strong>Pregnant Women:</strong> Fetal risk consideration, maternal-fetal benefit assessment. FDA pregnancy categories, teratogenicity data.</p>

        <h4>ğŸ›ï¸ Institutional Review Board (IRB)</h4>
        <p><strong>IRB Composition Requirements:</strong></p>
        <ul>
            <li>â‰¥5 members</li>
            <li>Gender/racial diversity</li>
            <li>Scientific ve non-scientific expertise</li>
            <li>Community representative (non-affiliated member)</li>
            <li>No conflicts of interest</li>
        </ul>

        <p><strong>Review Categories:</strong></p>
        <ul>
            <li><strong>Exempt:</strong> Minimal risk, specific categories</li>
            <li><strong>Expedited:</strong> Minimal risk, specific procedures list</li>
            <li><strong>Full Board:</strong> Greater than minimal risk, vulnerable populations</li>
        </ul>

        <h4>âš–ï¸ Risk-Benefit Analysis</h4>
        <p><strong>Risk Assessment:</strong> Physical, psychological, social, economic, legal risks evaluation. Probability Ã— severity matrix.</p>

        <p><strong>Benefit Assessment:</strong> Individual benefits vs societal benefits. Direct participant benefit vs knowledge generation.</p>

        <p><strong>Risk Minimization:</strong> Study design modifications, safety monitoring, data safety monitoring board (DSMB) implementation.</p>
    </div>

    <div class="sidebar" id="sidebar-21">
        <h3>ğŸƒâ€â™‚ï¸ Spor Bilimlerinde Etik: Ã–zel Durumlar</h3>
        <h4>ğŸ‘¶ Ã‡ocuk ve GenÃ§ Sporcular</h4>
        <p><strong>Developmental Considerations:</strong> Physical, cognitive, emotional development stages'Ä±n research participation'a etkisi. Growth spurts, psychological maturation, social pressure factors.</p>

        <p><strong>Parental Permission + Child Assent:</strong> Dual consent requirement. Child assent â‰¥7 yaÅŸ iÃ§in recommended. Age-appropriate explanation materials development.</p>

        <p><strong>Long-term Impact Assessment:</strong> Childhood research participation'Ä±n adult life'a potential effects. Career trajectory, body image, psychological well-being consideration.</p>

        <p><strong>Training Load Ethics:</strong> Developmentally appropriate training volume, intensity. Overuse injury prevention, burnout risk assessment. Fun ve enjoyment preservation priority.</p>

        <h4>ğŸ† Elite Sporcular</h4>
        <p><strong>Performance Pressure:</strong> Research participation'Ä±n competitive performance'a potential impact. Training disruption, psychological stress consideration.</p>

        <p><strong>Career Impact:</strong> Research findings'lerin sponsorship, team selection, public image effects. Confidentiality challenges high-profile athletes iÃ§in.</p>

        <p><strong>Dual Relationships:</strong> Researcher-coach, researcher-sport scientist conflicts. Professional boundary maintenance, objectivity preservation.</p>

        <p><strong>Media Attention:</strong> Research findings'lerin media coverage, misinterpretation risks. Public communication responsibility, sensationalism prevention.</p>

        <h4>âš•ï¸ Yaralanma ve Risk</h4>
        <p><strong>Exercise-Induced Injury Risk:</strong> Maximal effort tests, novel exercise protocols safety assessment. Pre-participation screening necessity.</p>

        <p><strong>Informed Consent Specificity:</strong> Exercise-specific risks detailed explanation. Previous injury history, current health status disclosure.</p>

        <p><strong>Emergency Preparedness:</strong> Medical personnel availability, emergency action plans. AED access, emergency contact protocols.</p>

        <p><strong>Return-to-Play Decisions:</strong> Research participation'Ä±n injury recovery'e etkisi. Clinical decision independence from research interests.</p>

        <h4>ğŸ§¬ Genetic Testing ve Privacy</h4>
        <p><strong>Genetic Discrimination Risk:</strong> Insurance, employment discrimination potential. Genetic Information Nondiscrimination Act (GINA) protections.</p>

        <p><strong>Family Implications:</strong> Genetic findings'lerin family members'a implications. Incidental findings disclosure protocols.</p>

        <p><strong>Data Storage Security:</strong> Long-term genetic data storage, access controls. De-identification challenges, re-identification risks.</p>

        <h4>ğŸ­ Performance Enhancement</h4>
        <p><strong>Ergogenic Aid Research:</strong> Legal vs banned substances research. WADA prohibited list compliance, athlete eligibility protection.</p>

        <p><strong>Competitive Advantage:</strong> Research findings'lerin competitive advantage creation ethics. Fair play principles, sport integrity preservation.</p>

        <p><strong>Technology Integration:</strong> Wearable devices, performance monitoring ethics. Privacy, data ownership, competitive intelligence concerns.</p>

        <h4>ğŸŒ Cultural Sensitivity</h4>
        <p><strong>Cross-cultural Research:</strong> Cultural values, practices respect. Western research paradigms'Ä±n non-Western populations'a applicability.</p>

        <p><strong>Religious Considerations:</strong> Dietary restrictions, modesty requirements, religious holidays respect. Research protocol adaptation necessity.</p>

        <p><strong>Language Barriers:</strong> Interpreter services, translated materials accuracy. Cultural concepts translation challenges.</p>
    </div>

    <div class="sidebar" id="sidebar-22">
        <h3>ğŸ“ˆ Veri Analizi: Modern Ä°statistiksel YaklaÅŸÄ±mlar</h3>
        <h4>ğŸ¯ Intention-to-Treat vs Per-Protocol</h4>
        <p><strong>Intention-to-Treat (ITT) Analysis:</strong> Original treatment assignment'a gÃ¶re analysis, adherence level'Ä±na bakÄ±lmaksÄ±zÄ±n. Pragmatic effectiveness, real-world implementation reflection.</p>

        <p><strong>Per-Protocol (PP) Analysis:</strong> Treatment'Ä± protocol'e gÃ¶re complete eden participants'larÄ±n analysis'i. Efficacy assessment, biological effect estimation.</p>

        <p><strong>Modified ITT (mITT):</strong> Post-randomization exclusions ile ITT principle'Ä±nÄ±n relaxation'Ä±. Practical compromise, regulatory acceptance.</p>

        <p><strong>As-Treated Analysis:</strong> Actual treatment received'a gÃ¶re analysis. Crossover, treatment switching situations'da useful.</p>

        <h4>ğŸ“Š Missing Data Strategies</h4>
        <p><strong>Missing Data Mechanisms:</strong></p>
        <ul>
            <li><strong>MCAR (Missing Completely at Random):</strong> Missing probability observed variables'dan independent</li>
            <li><strong>MAR (Missing at Random):</strong> Missing probability observed variables'a dependent, unobserved variables'dan independent</li>
            <li><strong>MNAR (Missing Not at Random):</strong> Missing probability unobserved values'a dependent</li>
        </ul>

        <p><strong>Traditional Approaches:</strong></p>
        <ul>
            <li><strong>Complete Case Analysis:</strong> Listwise deletion, unbiased under MCAR</li>
            <li><strong>Last Observation Carried Forward (LOCF):</strong> Conservative approach, bias risk yÃ¼ksek</li>
        </ul>

        <p><strong>Modern Methods:</strong></p>
        <ul>
            <li><strong>Multiple Imputation (MI):</strong> Rubin's method, uncertainty incorporation</li>
            <li><strong>Maximum Likelihood (ML):</strong> Direct likelihood analysis, MAR assumption</li>
            <li><strong>Inverse Probability Weighting:</strong> Selection probability modeling</li>
        </ul>

        <h4>ğŸ“‰ Interim Analysis ve Monitoring</h4>
        <p><strong>Group Sequential Methods:</strong> Multiple interim looks, Type I error control. O'Brien-Fleming, Pocock boundaries.</p>

        <p><strong>Adaptive Designs:</strong> Pre-planned modifications based on interim data. Sample size re-estimation, treatment arm dropping.</p>

        <p><strong>Futility Analysis:</strong> Early termination for lack of benefit. Conditional power, predictive power calculations.</p>

        <h4>ğŸ” Multiple Comparisons</h4>
        <p><strong>Family-wise Error Rate (FWER) Control:</strong></p>
        <ul>
            <li><strong>Bonferroni Correction:</strong> Î±/k adjustment, conservative</li>
            <li><strong>Holm-Bonferroni:</strong> Step-down procedure, more powerful</li>
            <li><strong>Sidak Correction:</strong> 1-(1-Î±)^(1/k), independence assumption</li>
        </ul>

        <p><strong>False Discovery Rate (FDR) Control:</strong></p>
        <ul>
            <li><strong>Benjamini-Hochberg:</strong> FDR â‰¤ Î± control</li>
            <li><strong>Benjamini-Yekutieli:</strong> Positive dependency correction</li>
        </ul>

        <h4>ğŸ² Bayesian Methods</h4>
        <p><strong>Prior Information Integration:</strong> Previous research, expert opinion incorporation. Conjugate priors, non-informative priors.</p>

        <p><strong>Posterior Distribution:</strong> Prior Ã— Likelihood combination. Credible intervals vs confidence intervals interpretation.</p>

        <p><strong>Bayesian Adaptive Trials:</strong> Continuous learning, real-time adaptation. Response adaptive randomization, dose finding studies.</p>

        <h4>ğŸ“Š Sensitivity Analysis</h4>
        <p><strong>Assumption Testing:</strong> Key assumptions'larÄ±n violation'Ä± durumunda results stability assessment.</p>

        <p><strong>Tipping Point Analysis:</strong> Conclusions'Ä±n change olmasÄ± iÃ§in gerekli assumption violation degree.</p>

        <p><strong>Best-Worst Case Scenarios:</strong> Missing data'nÄ±n extreme assumptions altÄ±nda analysis.</p>
    </div>

    <div class="sidebar" id="sidebar-23">
        <h3>ğŸ“ Bilimsel Raporlama: EQUATOR Guidelines</h3>
        <h4>ğŸŒ EQUATOR Network</h4>
        <p><strong>Enhancing the QUAlity and Transparency Of health Research:</strong> 2008'de establish edilmiÅŸ international initiative. Research reporting quality'yi improve etmek iÃ§in evidence-based guidelines development ve dissemination.</p>

        <p><strong>EQUATOR Mission:</strong> Accurate, complete, transparent research reporting promotion. Waste reduction in research, evidence synthesis improvement.</p>

        <h4>ğŸ“Š CONSORT Statement</h4>
        <p><strong>CONsolidated Standards of Reporting Trials:</strong> RCT reporting iÃ§in gold standard. 1996'da initial version, 2001 ve 2010 major updates.</p>

        <p><strong>CONSORT 2010 Checklist:</strong> 25 items, randomized trials'larÄ±n complete reporting ensure etmek iÃ§in. Title, abstract'tan discussion'a comprehensive coverage.</p>

        <p><strong>CONSORT Flow Diagram:</strong> Participant flow'un visual representation. Enrollment'tan analysis'e participant numbers tracking.</p>

        <p><strong>CONSORT Extensions:</strong></p>
        <ul>
            <li>CONSORT-Cluster: Cluster randomized trials</li>
            <li>CONSORT-Non-inferiority: Non-inferiority ve equivalence trials</li>
            <li>CONSORT-Pragmatic: Pragmatic trials</li>
            <li>CONSORT-Pilot: Pilot ve feasibility studies</li>
        </ul>

        <h4>ğŸ” STROBE Statement</h4>
        <p><strong>STrengthening the Reporting of OBservational studies in Epidemiology:</strong> Observational studies (cohort, case-control, cross-sectional) reporting guideline.</p>

        <p><strong>STROBE Checklist:</strong> 22 items, study design type'Ä±na gÃ¶re applicable items variation. Methods'tan discussion'a systematic coverage.</p>

        <p><strong>Key Reporting Elements:</strong></p>
        <ul>
            <li>Study design clear identification</li>
            <li>Setting ve participants detailed description</li>
            <li>Variable definitions, measurement methods</li>
            <li>Statistical methods explanation</li>
            <li>Results presentation without bias</li>
            <li>Limitations honest discussion</li>
        </ul>

        <h4>ğŸ“š PRISMA Statement</h4>
        <p><strong>Preferred Reporting Items for Systematic Reviews and Meta-Analyses:</strong> Sistematik derleme ve meta-analiz reporting standard.</p>

        <p><strong>PRISMA 2020:</strong> Latest update, 27-item checklist + flow diagram. Search strategy'den conclusions'a comprehensive guidance.</p>

        <p><strong>PRISMA Flow Diagram:</strong> Study selection process visualization. Database search'ten final inclusion'a systematic tracking.</p>

        <h4>ğŸ¯ SPIRIT Protocol</h4>
        <p><strong>Standard Protocol Items: Recommendations for Interventional Trials:</strong> Clinical trial protocol writing guideline.</p>

        <p><strong>SPIRIT Checklist:</strong> 33 items, protocol development phase iÃ§in guidance. Administrative information'dan ethics/dissemination'a complete coverage.</p>

        <h4>ğŸ‘¥ COREQ Guidelines</h4>
        <p><strong>COnsolidated criteria for REporting Qualitative research:</strong> Qualitative research reporting standards.</p>

        <p><strong>32-item Checklist:</strong> Research team, study design, data analysis reporting iÃ§in systematic approach.</p>

        <h4>ğŸ©º STARD Statement</h4>
        <p><strong>STAndards for Reporting Diagnostic accuracy studies:</strong> Diagnostic test accuracy studies reporting guideline.</p>

        <p><strong>STARD 2015:</strong> 30-item checklist, diagnostic accuracy assessment comprehensive reporting.</p>

        <h4>ğŸ“Š Journal Implementation</h4>
        <p><strong>Editorial Policies:</strong> Major medical journals'larÄ±n EQUATOR guidelines adoption. Manuscript submission requirements'a integration.</p>

        <p><strong>Peer Review Process:</strong> Reviewers'larÄ±n reporting guidelines compliance assessment. Quality improvement systematic approach.</p>
    </div>

    <div class="sidebar" id="sidebar-24">
        <h3>ğŸ”¬ Ã‡aÄŸdaÅŸ AraÅŸtÄ±rma YÃ¶nelimleri</h3>
        <h4>ğŸ¯ Precision Medicine</h4>
        <p><strong>Individualized Treatment Approach:</strong> Genetic, environmental, lifestyle factors'a gÃ¶re personalized interventions. "One size fits all" yaklaÅŸÄ±mÄ±ndan individual variability recognition'a transition.</p>

        <p><strong>Pharmacogenomics in Sports:</strong> Drug metabolism genetic variations'Ä±n supplement/medication response'a etkisi. CYP450 enzyme polymorphisms, caffeine metabolism individual differences.</p>

        <p><strong>Nutrigenomics:</strong> Gene-nutrient interactions'Ä±n performance'a etkisi. ACTN3 gene (speed gene), MCT1 gene (lactate transport) variations'Ä±n dietary recommendations'a influence.</p>

        <p><strong>Exercise Genomics:</strong> Training response genetic predictors. ACE gene polymorphisms'Ä±n endurance training adaptations'a etkisi. Individual training program optimization potential.</p>

        <h4>ğŸ“Š Big Data Analytics</h4>
        <p><strong>Multi-omics Integration:</strong> Genomics, proteomics, metabolomics data'nÄ±n combined analysis. Systems biology approach, holistic athlete profiling.</p>

        <p><strong>Wearable Device Data:</strong> Continuous physiological monitoring, 24/7 data collection. Heart rate variability, sleep patterns, recovery metrics integration.</p>

        <p><strong>Performance Analytics:</strong> Video analysis, GPS tracking, accelerometry data fusion. Team sports'da tactical analysis, individual performance optimization.</p>

        <p><strong>Electronic Health Records:</strong> Longitudinal health data, injury patterns analysis. Population health insights, risk prediction modeling.</p>

        <h4>ğŸ¤– Machine Learning Applications</h4>
        <p><strong>Supervised Learning:</strong> Prediction models for performance, injury risk. Random forests, support vector machines, neural networks application.</p>

        <p><strong>Unsupervised Learning:</strong> Pattern recognition, athlete clustering. Principal component analysis, k-means clustering, hidden patterns discovery.</p>

        <p><strong>Deep Learning:</strong> Image recognition (biomechanical analysis), natural language processing (literature mining). Convolutional neural networks, recurrent neural networks.</p>

        <p><strong>Reinforcement Learning:</strong> Optimal training strategy development, game theory applications. Dynamic programming, multi-armed bandit problems.</p>

        <h4>ğŸ“± Digital Biomarkers</h4>
        <p><strong>Smartphone-based Assessment:</strong> Gait analysis, reaction time, cognitive function measurement. Accessible, continuous monitoring capabilities.</p>

        <p><strong>Social Media Analysis:</strong> Mental health indicators, motivation patterns. Natural language processing, sentiment analysis applications.</p>

        <p><strong>Digital Therapeutics:</strong> App-based interventions, behavior change techniques. Evidence-based digital health solutions, clinical trial validation.</p>

        <h4>ğŸ”„ Adaptive Trial Designs</h4>
        <p><strong>Flexible Study Modification:</strong> Pre-planned adaptations based on interim data. Sample size re-estimation, treatment arm modification, population enrichment.</p>

        <p><strong>Bayesian Adaptive Designs:</strong> Continuous learning algorithms, real-time decision making. Response-adaptive randomization, dose optimization.</p>

        <p><strong>Platform Trials:</strong> Multiple treatments evaluation within single study framework. Master protocol approach, efficiency improvement.</p>

        <h4>ğŸŒ Real-World Evidence</h4>
        <p><strong>Pragmatic Trials:</strong> Real-world effectiveness assessment. Broad inclusion criteria, flexible protocols, community-based implementation.</p>

        <p><strong>Registry Studies:</strong> Large-scale observational data analysis. Long-term outcomes tracking, rare event detection.</p>

        <p><strong>Comparative Effectiveness Research:</strong> Multiple intervention comparisons, decision-making support. Health technology assessment, policy implications.</p>
    </div>

    <div class="sidebar" id="sidebar-25">
        <h3>ğŸ¯ Ã–zet ve Gelecek YÃ¶nelimleri</h3>
        <h4>ğŸ”® AraÅŸtÄ±rma TasarÄ±mÄ±nÄ±n EvolÃ¼syonu</h4>
        <p>21. yÃ¼zyÄ±lda araÅŸtÄ±rma tasarÄ±mÄ±, technological advancement ve methodological innovation ile rapid transformation yaÅŸamaktadÄ±r. Traditional RCT approach'tan adaptive, personalized, technology-enhanced designs'a transition gÃ¶zlemlenmektedir.</p>

        <p><strong>Paradigm Shifts:</strong></p>
        <ul>
            <li>Static â†’ Dynamic designs (adaptive trials)</li>
            <li>Population-based â†’ Individual-based (precision medicine)</li>
            <li>Single timepoint â†’ Continuous monitoring (digital health)</li>
            <li>Hypothesis-driven â†’ Data-driven (machine learning)</li>
        </ul>

        <h4>ğŸŒ Open Science Movement</h4>
        <p><strong>Reproducibility Crisis Response:</strong> 2010'larda baÅŸlayan replication crisis, research practices'Ä±n fundamental re-evaluation'Ä±nÄ± trigger etmiÅŸtir.</p>

        <p><strong>Open Science Practices:</strong></p>
        <ul>
            <li><strong>Pre-registration:</strong> Study protocols'larÄ±n public registration, selective reporting prevention</li>
            <li><strong>Data Sharing:</strong> Raw data availability, secondary analysis facilitation</li>
            <li><strong>Open Access Publishing:</strong> Research findings'lerin free access, knowledge democratization</li>
            <li><strong>Collaborative Research:</strong> Multi-site studies, large-scale collaboration networks</li>
        </ul>

        <h4>ğŸ¯ Spor Bilimlerinde Future Directions</h4>
        <p><strong>Personalized Sports Science:</strong> Individual response variability recognition, customized intervention development. Genetic profiling, biomarker-guided training prescription.</p>

        <p><strong>Technology Integration:</strong> Artificial intelligence, virtual reality, augmented reality applications. Immersive training environments, real-time biofeedback systems.</p>

        <p><strong>Ecological Validity Enhancement:</strong> Laboratory-field gap bridging. Natural environment research, ecological momentary assessment.</p>

        <p><strong>Interdisciplinary Approach:</strong> Engineering, computer science, psychology, nutrition disciplines'Ä±n integration. Systems approach, holistic athlete development.</p>

        <h4>ğŸš§ Methodological Challenges</h4>
        <p><strong>Data Volume Explosion:</strong> Big data analysis capabilities, storage infrastructure requirements. Statistical power abundance, multiple testing concerns.</p>

        <p><strong>Privacy/Ethics Balance:</strong> Data protection regulations (GDPR, HIPAA) compliance. Individual privacy vs scientific progress tension.</p>

        <p><strong>Reproducibility Assurance:</strong> Complex algorithms transparency, black box problem. Interpretability vs accuracy trade-off.</p>

        <h4>ğŸ“š Educational Implications</h4>
        <p><strong>Curriculum Modernization:</strong> Traditional statistics education'Ä±n data science skills ile supplementation. Programming, machine learning, data visualization competencies.</p>

        <p><strong>Critical Appraisal Skills:</strong> Rapidly evolving methodologies'Ä±n evaluation ability. Evidence quality assessment, bias recognition training.</p>

        <p><strong>Ethical Reasoning:</strong> Complex ethical scenarios'da decision-making skills. Technology ethics, research integrity emphasis.</p>

        <h4>ğŸ”® Future Research Questions</h4>
        <p>Gelecek araÅŸtÄ±rmalar increasingly complex, multifaceted questions'Ä± address edecek:</p>
        <ul>
            <li>Individual response heterogeneity'nin mechanisms'larÄ± nelerdir?</li>
            <li>Technology-mediated interventions'Ä±n long-term effectiveness'i nasÄ±ldÄ±r?</li>
            <li>Precision medicine approaches'Ä±n cost-effectiveness'i nedir?</li>
            <li>AI-assisted decision making'in clinical/practical implications'larÄ± nelerdir?</li>
        </ul>

        <p><strong>Final Note:</strong> AraÅŸtÄ±rma tasarÄ±mÄ±, static methodology deÄŸil, dynamic, evolving discipline'dÄ±r. Future sports scientists, methodological flexibility, technological literacy, ve ethical sensitivity ile equipped olmalÄ±dÄ±r.</p>
    </div>

    <button class="notes-toggle" onclick="toggleSidebar()">ğŸ“š Ders NotlarÄ±</button>

    <div class="progress">
        <span id="slideNumber">1 / 25</span>
    </div>

    <div class="controls">
        <button class="btn" id="prevBtn" onclick="previousSlide()" disabled>â¬…ï¸ Ã–nceki</button>
        <button class="btn" id="nextBtn" onclick="nextSlide()">Sonraki â¡ï¸</button>
    </div>

    <script>
        let currentSlide = 0;
        const slides = document.querySelectorAll('.slide');
        const sidebars = document.querySelectorAll('.sidebar');
        const totalSlides = slides.length;

        function showSlide(index) {
            // Hide all slides and sidebars
            slides.forEach(slide => slide.classList.remove('active'));
            sidebars.forEach(sidebar => sidebar.classList.remove('active'));

            // Show current slide
            slides[index].classList.add('active');
            // Reset scroll position when changing slides
            slides[index].scrollTop = 0;

            // Show corresponding sidebar (if exists)
            const correspondingSidebar = document.getElementById(`sidebar-${index + 1}`);
            if (correspondingSidebar) {
                correspondingSidebar.classList.add('active');
            }

            // Update counter
            document.getElementById('slideNumber').textContent = `${index + 1} / ${totalSlides}`;

            // Update button states
            document.getElementById('prevBtn').disabled = index === 0;
            document.getElementById('nextBtn').disabled = index === totalSlides - 1;
        }

        function nextSlide() {
            if (currentSlide < totalSlides - 1) {
                currentSlide++;
                showSlide(currentSlide);
            }
        }

        function previousSlide() {
            if (currentSlide > 0) {
                currentSlide--;
                showSlide(currentSlide);
            }
        }

        function toggleSidebar() {
            const activeSidebar = document.querySelector('.sidebar.active');
            if (activeSidebar) {
                activeSidebar.style.display = activeSidebar.style.display === 'none' ? 'block' : 'none';
            }
        }

        // Fullscreen functionality
        function toggleFullscreen() {
            if (!document.fullscreenElement) {
                document.documentElement.requestFullscreen().catch(err => {
                    console.log(`Error attempting to enable full-screen mode: ${err.message}`);
                });
            } else {
                document.exitFullscreen();
            }
        }

        // Double click for fullscreen
        document.addEventListener('dblclick', function(event) {
            if (event.target.closest('.slide')) {
                toggleFullscreen();
            }
        });

        // Advanced keyboard navigation
        document.addEventListener('keydown', function(event) {
            const activeSlide = document.querySelector('.slide.active');
            switch(event.key) {
                case 'ArrowRight':
                    // Only navigate to next slide if not at bottom of current slide
                    if (activeSlide && activeSlide.scrollTop + activeSlide.clientHeight >= activeSlide.scrollHeight - 10) {
                        event.preventDefault();
                        nextSlide();
                    }
                    break;
                case ' ':
                    // Space bar scrolls down within slide, or goes to next slide
                    if (activeSlide && activeSlide.scrollTop + activeSlide.clientHeight < activeSlide.scrollHeight - 10) {
                        event.preventDefault();
                        activeSlide.scrollBy(0, 200);
                    } else {
                        event.preventDefault();
                        nextSlide();
                    }
                    break;
                case 'ArrowLeft':
                    // Only navigate to previous slide if at top of current slide
                    if (activeSlide && activeSlide.scrollTop <= 10) {
                        event.preventDefault();
                        previousSlide();
                    }
                    break;
                case 'ArrowUp':
                    // Scroll up within slide
                    if (activeSlide) {
                        event.preventDefault();
                        activeSlide.scrollBy(0, -100);
                    }
                    break;
                case 'ArrowDown':
                    // Scroll down within slide
                    if (activeSlide) {
                        event.preventDefault();
                        activeSlide.scrollBy(0, 100);
                    }
                    break;
                case 'Home':
                    event.preventDefault();
                    currentSlide = 0;
                    showSlide(currentSlide);
                    break;
                case 'End':
                    event.preventDefault();
                    currentSlide = totalSlides - 1;
                    showSlide(currentSlide);
                    break;
                case 'n':
                case 'N':
                    toggleSidebar();
                    break;
                case 'F11':
                    event.preventDefault();
                    toggleFullscreen();
                    break;
                case 'Escape':
                    if (document.fullscreenElement) {
                        event.preventDefault();
                        document.exitFullscreen();
                    }
                    break;
            }
        });

        // Mouse wheel navigation
        document.addEventListener('wheel', function(event) {
            const activeSlide = document.querySelector('.slide.active');
            if (!activeSlide) return;

            if (event.deltaY > 0) {
                // Scrolling down
                if (activeSlide.scrollTop + activeSlide.clientHeight >= activeSlide.scrollHeight - 10) {
                    event.preventDefault();
                    nextSlide();
                }
            } else {
                // Scrolling up
                if (activeSlide.scrollTop <= 10) {
                    event.preventDefault();
                    previousSlide();
                }
            }
        }, { passive: false });

        // Mobile touch support
        let touchStartX = 0;
        let touchStartY = 0;
        let touchEndX = 0;
        let touchEndY = 0;

        document.addEventListener('touchstart', function(event) {
            touchStartX = event.changedTouches[0].screenX;
            touchStartY = event.changedTouches[0].screenY;
        });

        document.addEventListener('touchend', function(event) {
            touchEndX = event.changedTouches[0].screenX;
            touchEndY = event.changedTouches[0].screenY;
            handleSwipe();
        });

        function handleSwipe() {
            const deltaX = touchEndX - touchStartX;
            const deltaY = touchEndY - touchStartY;
            const minSwipeDistance = 50;

            if (Math.abs(deltaX) > Math.abs(deltaY) && Math.abs(deltaX) > minSwipeDistance) {
                if (deltaX > 0) {
                    // Swipe right - previous slide
                    previousSlide();
                } else {
                    // Swipe left - next slide
                    nextSlide();
                }
            }
        }

        // Initialize
        showSlide(0);
    </script>
</body>
</html>